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ABSTRACT 
Carvone  occurs  naturally  as  dextrorotatory  (d-)  and  levorotatory  (l-)  enantiomers  in  several  food 
items; these may also be used as a pesticide, food flavouring, feed flavouring, in feed additive, in 
personal care products and as (veterinary) medicine. In order to improve coherence regarding the risk 
assessment  of  carvone  in  the  different  food  and  feed  sector  areas,  EFSA  asked  its  Scientific 
Committee  to  establish  a  single  ADI  for  carvone,  estimate  the  overall  exposure  of  European 
consumers,  and  quantify  the  contribution  for  each  source  of  exposure  to  the  overall  exposure  of 
carvone. Having reviewed the information available the Scientific Committee decided to address d-
carvone and l-carvone separately and limit its assessment to the oral intake of d- and l-carvone. The 
Scientific Committee established an ADI of 0.6 mg/kg bw/day for d-carvone, based on the BMDL10 
of 60 mg/kg bw/day for an increase in relative liver weight in the rat 90-day studies and an uncertainty 
factor of 100. The Scientific Committee could not establish an ADI for l-carvone because of a lack of 
toxicological  data  for  this  enantiomer.  The  highest  level  of  aggregated  exposure  to  d-carvone  is 
estimated to be 0.60 mg/kg bw/day, i.e. is at the level of the ADI  established for d-carvone. The 
highest level of aggregated exposure to l-carvone is three-fold that of d-carvone. In view of  key 
uncertainties 1) on the toxicity of l-carvone, 2) on the biological relevance of the endpoint selected to 
establish the ADI for d-carvone and its use as a surrogate for the observed lethality in tested animals, 
3) whether d- and l-carvone should be considered together for possible combined effects and 4) in the 
aggregated  exposure  assessments  to  d-  and  to  l-carvone,  the  Scientific  Committee  recommended 
generating additional data to refine the current risk assessment.  
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SUMMARY 
Carvone occurs naturally as dextrorotatory (d-) and levorotatory (l-) enantiomers in several food items 
such as mint and caraway; the enantiomers may also be used as a pesticide (sprout inhibitor), food 
flavouring, feed flavouring or, together with other active substances, in a zootechnical feed additive. In 
addition it can be used in personal care products and as (veterinary) medicine. Evaluations of this 
compound have therefore been performed by different scientific bodies, by the European Commission 
and more recently by EFSA.  
In order to improve coherence regarding the risk assessment of carvone in the different food and feed 
sector  areas  of  the  European  Food  Safety  Authority,  EFSA  asked  its  Scientific  Committee  to  1) 
establish a single ADI for carvone to be used at European level, regardless of the food sector area, and 
considering all previous evaluations, 2) estimate the overall exposure of European consumers to the 
carvone resulting from its various uses, and 3) quantify the contribution for each source of exposure to 
the overall exposure of carvone. Having reviewed the data available and the previous assessments 
done, the Scientific Committee decided to address d-carvone and l-carvone separately and limit its 
assessment to the oral intake of d- and l-carvone. In view of an expected request for extending the 
application  of  d-carvone  as  an  anti-sprouting  agent  to  ware  and  starch  potatoes;  the  Scientific 
Committee decided to include also this use in its assessment. 
The Scientific Committee considered the data available for d-carvone and selected the liver effects as 
the most likely relevant endpoint to be used as the basis for risk assessment. The Scientific Committee 
established an ADI of 0.6 mg/kg bw/day for d-carvone, based on the BMDL10 of 60 mg/kg bw/day for 
an increase in relative liver weight in the rat 90-day studies and an uncertainty factor of 100. The 
Scientific Committee could not derive an ADI for l-carvone because of a lack of toxicological data for 
this enantiomer. 
The Scientific Committee considered oral exposure of humans to carvone from its presence in natural 
sources through the diet where it is a normal constituent, its current use as a pesticide, its use as 
flavouring substances, its use as a feed additive, its use as a (veterinary) medicinal product, and its use 
in  personal  care  products  (toothpaste,  mouthwash).  Based  on  the  available  data  the  Scientific 
Committee concluded that the highest aggregate exposure estimate of d-carvone from these uses is 
0.59 mg/kg bw/day for high-level children consumers, which is marginally higher than that for high-
level adult consumers. The highest exposure estimate for d-carvone is therefore at the level of the ADI 
established  for  d-carvone.  The  Scientific  Committee  concluded  that  the  main  contributors 
(contributing over 10%) to the current overall oral exposure to d-carvone are in decreasing order: 
flavourings, personal care products, natural sources. Inclusion of exposure from the intended use of d-
carvone as anti-sprouting agent on ware and starch potatoes does not result in an exceedance of the 
ADI.  
The highest level of aggregated exposure to l-carvone is estimated to be 1.87 mg/kg bw/day for high-
level adult consumers. It is noted that this value is three fold that of d-carvone exposure. The main 
contributors to the overall oral exposure to l-carvone are in decreasing order: personal care products 
and flavourings. 
The Scientific Committee underlined the key uncertainties of this assessment 1) on the toxicity of l-
carvone, 2) on the biological relevance of the endpoint selected to establish the ADI for d-carvone and 
its use as a surrogate for the observed lethality in tested animals, 3) whether d- and l-carvone should 
be considered together for possible combined effects and 4) in the aggregated exposure assessments to 
d- and to l-carvone, because the exposure via dermal contact and inhalation is not included in the 
current assessment.  Safety assessment of carvone 
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The Scientific Committee recommends generating the following data to reduce the level of uncertainty 
and to refine the current risk assessment: 
  Toxicokinetic data for d- and l-carvone in rats;  
  Toxicity data for l-carvone; 
  Studies investigating the mode of action of both d- and l-carvone; 
  Validation of the concentration data from all sources used for the oral aggregated exposure 
assessment for d- and l-carvone; priority should be given to the main contributory sources 
(>10%); 
  Develop models to perform aggregate exposure assessment from different routes (oral-dermal-
inhalation).  In  order  to  do  this,  data  providing  information  on  the  relationship  between 
external and internal exposure for different routes are needed. 
 Safety assessment of carvone 
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BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY EFSA 
Carvone is a natural component in several food items such as mint and caraway but it may also be 
used as a pesticide, food flavouring, feed flavouring or, together with other active substances, in a 
zootechnical feed additive. Evaluations of this compound have therefore been performed by different 
scientific bodies and by the European Commission: initially by the Joint FAO/WHO Committee on 
Food Additives (JECFA) between 1968 and 2000, then as a pesticide active substance by the European 
Commission  in  2008  (in  application  of  Directive  91/414/EEC
4,  repealed  by  Regulation (EC) No 
1107/2009
5),  then  by  the  EFSA  Panel  on  Food  Contact  Materials,  Enzymes,  Flavourings  and 
Processing Aids (CEF) in 2011 and the latest evaluation by EFSA's Panel on Additives and Products 
or Substances used in Animal Feed (FEEDAP) in 2011. 
The JECFA established an acceptable daily intake (ADI) of 0-1 mg/kg body weight per day based on 
short-term studies  in  rats (WHO,  2000, 2004).  The  Standing Committee on the Food Chain and  
Animal Health (SCoFCAH) of the European Commission (EC) established an ADI of 0-0.025 mg/kg 
bodyweight per day based on a different short-term toxicity study in rats (EC, 2008), the CEF and 
FEEDAP Panels endorsed the assessment done by the JECFA. 
Activities in the field of food flavourings 
Regarding the evaluation of carvone in food, the genotoxicity of d-carvone was evaluated by the 
JECFA; it was concluded that d-carvone was not genotoxic and was not carcinogenic in mice. This 
evaluation of the JECFA was endorsed by the CEF Panel and d-carvone together with the structurally 
related l-carvone were cleared with respect to genotoxicity (EFSA CEF Panel, 2011a). Considering 
that the JECFA evaluated the two substances before 2000 and that no safety concerns were identified 
by the JECFA, EFSA was not required to re-evaluate their safety, in line with the provisions laid down 
in Commission Regulation (EC) No 1565/2000
6. Accordingly, both substances were included in the 
European Union list of flavouring substances in Regulation (EU) No 872/2012 (EU, 2012). 
Activities in the field of feed additives 
In  application  of  Article  4(1)  of  Regulation  (EC)  No  1831/2003
7,  which establishes  the  rules 
governing the Community authorisation of additives for use in  animal nutrition, EFSA’s FEEDAP 
Panel evaluated the product FRESTA
® F, minimum 0.35% carvone, to be used as a feed additive for 
weaned piglets (category: zootechnical additives) and the opinion has been adopted in April 2011.  
Currently the FEEDAP Panel is re-evaluating the compounds d- and l-carvone and their mixtures 
when used as flavourings in animal nutrition.  
The FEEDAP Panel took the JECFA evaluation on carvone as the basis for the assessment of d-
carvone in FRESTA
® F. An ADI of 1.0 mg/kg bodyweight per day was established for d-carvone 
based on a NOAEL of 93 mg/kg bw/day in a 3-month toxicity study in rat and by applying a safety 
factor of l00 (EFSA FEEDAP Panel, 2011).  
The  FEEDAP  Panel  was  at  that  time  aware  of  the  ADI  of  0.025  mg/kg  body  weight  per  day 
established by the EC SCoFCAH but could not assess the appropriateness of this ADI because the data 
considered by the European Commission was not made available to the Panel at that time.  
                                                       
4 Directive 91/414//EEC of 15 July 1991. OJ L 230, 19.08.1991, p. 1-32. 
5 Regulation (EC) No 1107/2009 of 21 October 2009. OJ L 309, 24.11.2009, p. 1-50. 
6 Regulation (EC) No 1565/2000 of 18 July 2000. OJ L 180, 19.7.2000, p. 8-16. 
7 Regulation (EC) No 1831/2003 of 22 September 2003. OJ L 268, 18.10.2003, p. 29. Safety assessment of carvone 
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Activities in the field of pesticides 
According to Article 12 of Regulation (EC) No 396/2005
8, which establishes the rules governing the 
setting of pesticide maximum residue  levels (MRLs) at European Union  level, EFSA is now also 
required to review the existing MRLs resulting from the pesticide use of carvone, which are currently 
established at the default MRL of 0.01 mg/kg for all commodities of plant and animal origin. The 
Pesticides Unit was mandated to carry out this exercise (M-2008-0600) and a question number related 
for the review of carvone MRLs was attributed  (EFSA-Q-2008-505). Considering however that 
carvone (mainly its d-enantiomer) may be used as a pesticide, food  flavouring or feed additive, and 
that it may also be present naturally in certain plants (e.g. caraway), the Pesticides Unit investigated 
the possibility to include carvone in Annex IV of Regulation (EC) No 396/2005, which includes all 
pesticide active substances that do not require the setting of MRLs. In fact, this annex includes, among 
others, pesticide active substances that may also be used in other sectors of the food chain (i.e. benzoic 
acid). Such compounds may be included in this annex provided that: 
  the contribution of the pesticide use to the overall exposure of the compound is minor; 
  the overall exposure to the compound does not pose any risk to European consumers. 
Although the data available to the Pesticides Unit are sufficient to estimate the exposure of European 
consumers to carvone residues resulting from its pesticide use, the Pesticides Unit is not in a position 
to  estimate  the  exposure  from  the  other  carvone  sources.  Moreover,  even  if  EFSA  was  not  yet 
involved in the activities of Directive 91/414/EEC when the ADI of 0.025 mg/kg bodyweight per day 
was established for carvone by the European Commission, EFSA and Member States are in principle 
legally bound to use this ADI when assessing the risk resulting from the use of carvone as a pesticide. 
Using this toxicological reference value, exceedances of the ADI are to be expected, not only from the 
use of carvone as a pesticide but also from the use of carvone as a food flavourings. 
Proposed way forward 
Considering that the evaluation made by the European Commission and the evaluation made by the 
JECFA, and endorsed by EFSA's CEF and FEEDAP Panels, are established from different datasets, it 
should be investigated which ADI is now the most appropriate to be used for carvone at European 
level, regardless of the food sector area. This assessment should take into consideration all previous 
evaluations. 
Considering  that  several  food  sector  areas  of  EFSA  are  involved,  in  line  with  Article  28(2)  of 
Regulation  (EC)  No  178/2002
9, the Scientific Committee is  deemed to be the m ost appropriate 
scientific body for performing this assessment. This assessment may then also serve as a basis for the 
EC SCoFCAH to change, if needed, the ADI established in the pesticide legislation. 
In order to improve coherence regarding the risk asses sment of carvone in the different food sector 
areas of the European Food Safety Authority, the Scientific Committee is requested to: 
  establish a single ADI for carvone to be used at European level, regardless of the food sector 
area, and considering all previous evaluations; 
  estimate the overall exposure of European consumers to the carvone resulting from its use as a 
pesticide, food flavouring, feed additive as well as its natural occurrence; 
  quantify the contribution for each source of exposure to the overall exposure of carvone. 
                                                       
8 Regulation (EC) No 396/2005 of 23 February 2005. OJ L 70, 16.03.2005, p. 1-16. 
9 Regulation (EC) No 178/2002 of 28 January 2002. OJ L 31, 1.2.2002, p. 1-24. 
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1.  INTRODUCTION 
Carvone  is  a  monoterpene  ketone  which  is  naturally  found  in  plants  and  seeds,  both  as  the 
dextrorotatory (d-carvone) and the levorotatory (l-carvone) enantiomers.  
1.1.  Nomenclature 
 
 
Identification numbers and nomenclature systems for the carvone enantiomers are given in Table 1. In 
this opinion the d-/l-nomenclature is used. 
Table 1:   Identification numbers and nomenclature systems for the carvone enantiomers 
EC Number  CAS Number  CIP convention  Fischer 
nomenclature 
Dexter/laevus 
218-827-2   2244-16-8   (S)-(+)-carvone  L(+)-carvone  d-carvone 
229-352-5   6485-40-1   (R)-(-)-carvone  D(-)-carvone  l-carvone 
 
1.2.  Physical and chemical properties 
d-Carvone and l-carvone are both colourless to pale yellow liquids with a characteristic caraway and 
spearmint odour respectively. Both are insoluble in water and glycerol, miscible with ethanol, and 
soluble in propylene glycol, fixed oils, and mineral oils. The boiling point is around 230°C at 755 mm 
for both d- and l- carvone, with a specific gravity of 0.96 at 20°C (NTP, 1990; US-EPA, 2009).  
1.3.  Analysis 
In regulatory frameworks, analytical methods are required to ensure identity and purity of regulated 
substances and to monitor their residues in food and feed.  
The  enantiomers  d-carvone  and  l-carvone  cannot  be  separated  with  standard  chromatographic 
techniques.  Therefore  no  distinction  can  be  made  between  these  stereoisomers,  unless  specific 
approaches, such as the use of chiral stationary phases in capillary gas chromatography or the use of 
chiral shift reagents in NMR spectroscopy, are employed. 
The data provided on the natural occurrence of carvone solely rely on literature. The quality of the 
analytical  approaches  underlying  the  reported  values  and  the  type  of  information  provided  differ 
substantially. On the one hand, the information given in several papers is limited to the yield of Safety assessment of carvone 
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essential oil isolated from the plant part and the percentage of carvone in the essential oil, without 
provision of analytical information substantiating the reported quantitative values, for example, by 
means of extraction efficiencies or chromatographic response factors. On the other hand, isotopically 
labelled carvone has been used as an internal standard, thus significantly increasing the accuracy of the 
quantification. Similarly, some of the papers report the occurrence of carvone, without specifying the 
enantiomers, whereas others employ the required enantioselective analyses and provide data for d- and 
l-carvone, respectively. In many cases, the number of samples of natural sources analysed is rather 
limited. 
No  description  of  analytical  methods  for  carvone  was  presented  in  the  JECFA  toxicological 
evaluations (WHO, 1980, 2000). The JECFA FAO specifications mention a GLC method for both d- 
and l-carvone. No analytical methods are described in the EMA evaluation of Carvi aetherolium, used 
as  a  veterinary  medicine  or  in  the  CEF  opinions  on  carvone  use  as  a  flavouring  agent.  For  the 
veterinary medicine use, it was concluded that it was unnecessary to establish MRLs for this use, and 
therefore no information on a Routine Analytical Method (RAM) was required. The recent ECHA 
Classification and Labeling assessment was based on the information present in the pesticide dossier. 
In the pesticide authorization dossier, analytical methods for the technical substance, the formulation 
and for the determination of residues in potato tubers were presented. 
For the quantitative determination of carvone in the technical substance and formulation, carvone was 
determined by capillary GC with dodecane as internal standard.  
Two methods were available to determine carvone in potato tubers. In both methods the potato sample 
was homogenized with methanol, followed by partition into either chloroform or dichloromethane. In 
the first method, analysis was performed by GC-FID fitted with a thermodesorption cold trap (TCT) 
injection system; in the second method, by GC-MS.  
For the first method, no validation data were supplied. For the second method, the LOQ was 0.05 
mg/kg, and mean recoveries ranged between 85 and 101%.  
In the peer-review process, the second analytical method was in principle considered to be suitable for 
enforcement purposes, however it was concluded that the method should be adapted with respect to 
solvents used to be suitable for incorporation in a standard multi-residue method. Furthermore, the 
method should be subjected to independent laboratory validation. 
For  the  determination  of  carvone  in  feed  additives,  premixtures  and  feedingstuffs,  the  applicant 
submitted  an  in-house  validated  method,  using  gas-chromatographic/mass-spectrometry  (GC/MS). 
Furthermore,  a  verification  study  compliant  with  the  EURL  technical  guide  was  submitted.  The 
performance characteristics were satisfactory. A limit of detection (LOD) and quantification (LOQ) of 
0.016 and 0.055 mg/kg of feedingstuffs, respectively were confirmed. 
Analyses of meat and blood samples from piglets fed FRESTA
® F for six weeks at the maximum 
recommended dosage (400 mg/kg feed) and tenfold the maximum dosage (4000 mg/kg feed) did not 
detect any d-carvone residues. The limit of detection (LOD) was 0.04 mg/kg in meat and 0.1 mg/l in 
blood.  No  further  information  on  the  analytical  method  used  was  available  in  the  EFSA  opinion 
(EFSA FEEDAP Panel, 2011). 
In  conclusion,  analytical  methods  are  available  to  determine  d-  and  l-carvone  in  food  and  feed; 
however carvone is not routinely incorporated in monitoring programmes. 
1.4.  Sources of carvone 
d-Carvone is present in the seeds of caraway (Carum carvi L.), in the aerial parts and the seeds of dill 
plants (Anethum graveolens L.), in the oil from the leaves and flowers of Chrysanthemum indicum L. Safety assessment of carvone 
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(Compositae), mandarin peel oil (Citrus reticulata Blanco, Rutaceae), ginger-grass oil, kuromoji oil, 
lavender oil, and many other essential oils (NTP, 1990). Caraway is one of the oldest herbs cultivated 
in Europe and is endemic of Northern and Central Europe, Siberia, Turkey, Iran, India and North 
Africa. Its first use was documented by the ancient Arabs, and Pliny the elder recommended it for 
hysterical complaints and pale complexions. Nowadays, caraway is cultivated throughout the globe 
from northern temperate to tropical climates, including Jamaica, India, Canada, United States and 
Australia.  
l-Carvone  imparts  the  odour  of  spearmint  and  constitutes  50-65%  of  the  essential  oil  from  the 
flowering tops of the spearmint plant Mentha spicata L. (M. viridis (L.) L.) Alternatively, l-carvone 
can also be synthethised from d-limonene (NTP, 1990; US-EPA, 2009).  
1.5.  Biosynthesis of carvone in plants 
In the caraway fruit, d-carvone is biosynthesised through a multi-step pathway starting from geranyl 
diphosphate which is firstly cyclised to d-limonene, then stored in essential oil ducts, further converted 
to d-trans-carveol by limonene-6-hydroxylase, and finally oxidised by a dehydrogenase to d-carvone 
(Bouwmeester et al., 1998).  
In a similar fashion, l-carvone is synthesised in the glandular trichomes of spearmint (Mentha spicata) 
through the cyclisation of the C10 isoprenoid intermediate geranyl pyrophosphate to the monoterpene 
hydrocarbon l-limonene then hydroxylated to l-carveol and subsequently dehydrogenated to l-carvone 
(Gerchenzon et al., 1989). 
1.6.  Uses of carvone:  
The following uses have been identified for carvone (WHO, 2000; US-EPA, 2009; EFSA FEEDAP 
Panel, 2011; EFSA, 2012; ECHA, 2013): 
  Pesticide: d-carvone is currently authorised as an anti-sprouting substance for seed potatoes. l-
Carvone (spearmint oil) is authorised as plant growth regulator for post-harvest treatment of 
potatoes. 
  Feed additive: d-carvone is used in a commercial product claimed to improve the growth rate 
of weaned piglets. 
  Veterinary  use:  Carvi  aetheroleum  (containing  d-carvone)  is  used  in  veterinary  medicinal 
products to facilitate breathing in new-borne animals, and to treat flatulence and disturbances 
of the stomach and the gut in farmed animals. 
  Flavouring substance and natural food occurrence: both d- and l-carvone are broadly used as 
flavouring substances in various food categories. In addition, foods containing carvone as 
naturally occurring constituent are used as ingredients with flavouring properties; for example, 
caraway seeds are used to flavour bread (e.g. rye bread), cheese, sauerkraut, candies, meat 
products, sauces and alcoholic liqueurs (e.g German Kummel).  
  Personal care products: d- and l-carvone are used in a variety of non-food consumer products, 
including  cosmetics  and  personal  care  products.  Some  of  these,  such  as  toothpaste  and 
mouthwash may result in oral intake of carvone. 
  Medicinal  use:  Carvi  aetheroleum  and  carvi  fructus  are  registered  as  herbal  medicinal 
products by the European Medicines Agency. Uses as a laxative, in colic treatment, as a breath 
freshener, or to help digestion in young children have been reported. Other properties claimed  Safety assessment of carvone 
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for  caraway  seeds  include  antispasmodic,  carminative,  emmenagogue,  expectorant, 
galactagogue, stimulant, stomachic and tonic properties (de Carvalho and da Fonseca, 2006).  
  Alternative use: natural insect repellent. No oral intake is expected. 
1.7.  Legislation 
1.7.1.  Legislation on flavourings 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EU, 1996) laid down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other flavouring substances in the EU. In application of that Regulation, a 
Register  of  flavouring  substances  used  in  or  on  foodstuffs  in  the  Member  States  was  adopted 
(Commission Decisions 1999/217/EC (EC, 1999), 2009/163/EC (EC, 2009)). The substances listed in 
the Register have been evaluated according to the evaluation programme laid down in Commission 
Regulation (EC) No 1565/2000 (EC, 2000). The Union list of flavouring substances for use in or on 
foods in the EU has been adopted by Commission Implementing Regulation (EU) N0 872/2012 (EU, 
2012);  d-Carvone  (FL  No.  07.146), l-carvone  (FL No.  07.147)  and  carvone (FL  No.  07.012)  are 
contained in this list.  
1.7.2.  Legislation on pesticides 
Regulation  (EC)  No  1107/2009  (and  before  14  June  2011  Directive  91/414/EEC)  concerning  the 
placing of plant protection products on the market states that active substances in plant protection 
products are only approved in the EU if it may be expected that their use will not have any harmful 
effects  on  human  and  animal  health  or  on  groundwater  or  any  unacceptable  influence  on  the 
environment.  
Since August 2002, EFSA has been responsible for the EU peer review of active substances used in 
plant protection products. 
Maximum Residue Levels (MRLs) are the upper legal concentrations for pesticide residues in or on 
food or feed based on good agricultural practices. MRLs can only be established when foods derived 
from  commodities  that  comply  with  the  respective  MRLs  do  not  cause  unacceptable  consumer 
exposure (consumer intake should not exceed the toxicological reference values). 
Regulation (EC) No 396/2005 establishes the MRLs of pesticides permitted in products of plant or 
animal origin intended for human or animal consumption. MRLs are derived after a comprehensive 
assessment of the properties of the active substance, and of the residue levels resulting from the good 
agricultural practices authorized at national level for the treated crops. 
This Regulation, fully applicable since September 2008, repeals the previous fragmentary legislation 
and replaces all national MRLs with harmonised EU MRLs for all foodstuffs.  
In conclusion, even if a substance is placed on the Union’s list of approved active substances, only 
uses not leading to quantifiable residues in food or feed can be authorized by Member States until 
MRLs are set at European Union’s level. Until that time a default MRL of 0.01 mg/kg is valid. 
Legal status of the use of d-carvone and spearmint oil (containing l-carvone) as pesticides 
Carvone was included in Annex I of Commission Directive 91/414/EEC on August 1st, 2008, by 
means of Commission Directive 2008/44/EC of April 4th, 2008. Although the text refers to ‘carvone’, 
it  is  stated  that  the  active  substance  shall  have  a  minimum  purity  of  930  g/kg  d-carvone  in  the 
technical product with a d/l ratio of at least 100:1. Therefore, it is actually d-carvone that is included in 
Annex I. According to Regulation (EU) No 540/2011, carvone is deemed to have been approved under  Safety assessment of carvone 
 
EFSA Journal 2014;12(7):3806  12 
Regulation (EC) No 1107/2009. As EFSA was not yet involved in the peer review of this active 
substance, there is no EFSA conclusion on the pesticide risk assessment of carvone available. 
As d-carvone was included in Annex I before the MRL Regulation (EC) 396/2005 came into force, 
existing  MRLs  need  to  be  reviewed  within one  year after  the im plementation  date  of 396/2005. 
However, until now, no MRLs have been set, and the default MRL of 0.01 mg/kg applies. 
Due to data gaps preventing the setting of MRLs,  d-carvone is currently authorised for use on seed 
potatoes only. However, the manufacturer now also wants to apply for authorization of use as a sprout 
suppressant on ware and starch potatoes (see Glossary), leading to residues up to 10 mg/kg. In May 
2010, the Rapporteur Member State (The Netherlands) proposed in its Article 12.2 evaluation that 
given the wide use of carvone as a flavouring agent and its natural occurrence, it could be considered 
to put carvone in Annex IV of the MRL Regulation. Annex IV lists pesticides for which no MRLs will 
be set because the residues resulting from pesticide use cannot be distinguished from levels arising 
naturally. 
Spearmint  oil  (containing  l-carvone)  was  included  in  Annex  I  of  Directive  91/414/EEC  on  18 
December 2008 pursuant to Article 24b of the Regulation (EC) No 2229/2004. This is a so called 
‘green  track’  substance  where  the  Commission,  on  the  basis  of  a  first  examination  of  the  draft 
assessment report (DAR), concluded that there were no harmful effects for this compound. It was 
therefore included in Annex I pending the formal peer review of the DAR by EFSA. It was therefore 
also temporarily included in Annex IV of the MRL regulation, pending finalisation of the evaluation 
under Directive 91/414/EEC and pending submission of EFSA’s reasoned opinion in accordance with 
Article 12(1). 
Meanwhile, the evaluation under Directive 91/414/EEC was finalised and a conclusion on the peer 
review of spearmint oil was issued by EFSA on 16 December 2011. A long list of data gaps was 
identified and the risk assessment could not be finalised. Despite the concerns raised by EFSA, the 
approval  of  the  compound  under  Regulation  (EC)  No  1107/2009  was  confirmed  by  means  of 
Commission Implementing Regulation (EU) No 608/2012 but the following restriction was included: 
“Only uses as plant growth regulator for postharvest treatment of potatoes may be authorised. Member 
States  shall  ensure  that  authorisations  provide  that  hot  fogging  is  performed  exclusively  in 
professional storage facilities and that the best available techniques are applied to exclude the release 
into  the  environment  of  the  product  (fogging  mist)  during  storage,  transport,  waste  disposal  and 
application.” The reasoning behind this decision is not known but most probably the compound was 
approved on the basis that it is a natural product present in food. The compound was therefore also 
maintained in Annex IV of the MRL regulation. 
The post-harvest use of spearmint oil on food/feed potatoes is authorised in a number of Member 
States such as BE, ES, IT, NL and UK. Therefore, the Scientific Committee concluded that spearmint 
oil is used not only on seed potatoes but could also be used on ware and starch potatoes. However 
based  on  the  wording  that  was  used  for  the  approval  of  the  compound  carvone,  the  Scientific 
Committee assumes that only the use of carvone as a sprout inhibitor on seed potatoes is authorised by 
Member States. 
1.7.3.  Legislation on feed additives 
Regulation (EC) No 1831/2003 provides the grounds and procedures for the authorisation of additives  
for use in animal nutrition. Article 10 of that Regulation provides for the re-evaluation of additives 
authorised  pursuant  to  Council  Directive  70/524/EEC :  d-carvone  and  l-carvone  were  authorised 
without a time limit in accordance with Directive 70/524/EEC as feed additives for use on all animal 
species as part of the group “ natural or corresponding synthetic chemically defined flavourings”. 
Until  a  decision  will  be  adopted  in  the  context  of  the  re-evaluation  procedure,  l-carvone  and  d- 
carvone  can  be  placed  on  the  market  and  used  as  feed  flavourings.  The  European  Commission 
received a request under Article 4 of Regulation (EC) No 1831/2003 for a new authorisation of the Safety assessment of carvone 
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product  FRESTA
®  F,  to  be  used  as  a  feed  additive  for  weaned  piglets  (category:  zootechnical 
additives; functional group: other zootechnical additives). According to Article 7(1) of Regulation 
(EC) No 1831/2003, this application was forwarded to EFSA who undertook an assessment in order to 
determine whether the feed additive complies with the conditions laid down in Article 5. The additive 
was authorised by Regulation (EU) 131/2012. The additive contain caraway oil as active substance (d-
carvone 3.5-6.0 mg/g).  
1.7.4.  Legislation on herbal medicinal products 
In Europe, herbal medicinal products are licensed and marketed according to Directive 2004/24/EC. 
The  National  competent  authorities  in  the  EU  member  states  are  responsible  for  applying  the 
provisions of the Directive. 
Herbal medicinal products must fall within one of the following three categories to reach the market: 
1.  Traditional use. A product can be classified under traditional medicinal use on the basis of 
sufficient safety data and plausible efficacy. The product is granted a traditional use registration by a 
Member State. 
2.  Well-established use. A product can be classified under well-established medicinal use if it 
has been demonstrated from scientific literature that the active substances of the medicinal products 
have been in well-established medicinal use within the European Union for at least ten years, with 
recognised efficacy and an acceptable level of safety. The product is granted a marketing authorisation 
usually by a Member State or by the European Medicines Agency. 
3.  Stand  alone.  A  product  can  be  authorised  after  evaluation  of  a  marketing  authorisation 
application consisting of only safety and efficacy data from the company’s own development or a 
combination of own studies and bibliographic data. The product is granted a marketing authorisation 
by a Member State or by the European Medicines Agency. 
Irrespective of the regulatory pathway to access the market, the quality of the herbal medicinal product 
must always be demonstrated. Carvi fructus (caraway fruit) and Carvi aetheroleum (caraway oil) are 
registered as herbal medicinal products, most probably via the ‘well-established use’ route. A call for 
scientific  data  for  further  evaluation  by  the  Committee  on  Herbal  Medicinal  Products  from  the 
European Medicines Agency is ongoing. 
1.7.5.  Legislation on veterinary medicinal products 
Regulation (EC) No. 470/2009 of the European Parliament and the Council (EU, 2009) laid down a 
procedure for the establishment of residue limits of pharmacologically active substances in foodstuffs 
of animal origin. A pharmacologically active substance may be used in food-producing animals only if 
evaluated favourably. Maximum residue limits are established for such substances where they are 
considered necessary for the protection of human health. Pharmacologically active substances and 
their  classification  regarding  maximum  residue  limits  are  set  out  in  the  Annex  of  Commission 
Regulation (EU) No. 37/2010. Carvi aetheroleum is the volatile oil obtained by steam distillation of 
ripe seeds of Carum Carvi L. The oil contains d-carvone (45 to 65%). Carvi aetheroleum has been 
included in the Annex of Reg. (EC) No. 470/2009 as ‘No MRL required, for all food producing 
species’. 
1.7.6.  Legislation on cosmetic and personal care products 
The EU Cosmetics Regulation (Regulation (EC) No 1223/2009 of the European Parliament and of the 
Council of 30 November 2009 on cosmetic products) covers the use of certain ingredients in cosmetic 
products.  CosIng  is  the  EC’s  database  with  information  on  cosmetic ingredients  contained in  the 
Cosmetics Regulation, the "Cosmetics Directive" 76/768/EEC (Cosmetics Directive) as amended, the Safety assessment of carvone 
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Inventory  of  Cosmetic  Ingredients,  and  the  opinions  on  cosmetic  substances  of  the  Scientific 
Committees (limited to those published on the internet).  
Carvone is listed as Carvone (CAS No. 99-49-0), l- carvone (CAS No. 6485-40-1), and d- carvone 
(CAS No. 2244-16-8) in the CosIng Inventory as a cosmetic ingredient for flavouring, masking, and 
perfuming. An opinion of the Scientfic Committee on Consumer Safety on fragrance allergens in 
cosmetic products (EC SCCS, 2011) has listed carvone (CAS Nos. 99-49-0, 6485-40-1 and 2244-16-8) 
among the established contact allergens (skin sensitisers) in humans. 
1.8.  Previous evaluations of carvone 
JECFA evaluated the safety of carvone as a flavouring substance on several occasions. A conditional 
ADI of 0-1.25 mg/kg bw/day for the d- and l-enantiomers was established at the 11
th meeting (1968), 
based on three studies (16 weeks and 27-28 weeks with a diet containing 0, 0.1 and 1% of carvone, 
and 1-year with a diet containing 0 or 0.25% carvone) where Osborne-Mendel rats were maintained on 
diets containing carvone. The d/l ratio was unspecified in the three studies. Rats exposed to 500 mg/kg 
bw/day for 16 weeks showed growth depression and testicular atrophy. Exposures to 50 mg/kg bw/day 
(27-28  weeks)  and  125  mg/kg  bw/day  did  not  display  any  adverse  effects  (Hagan  et  al.,  1967).  
JECFA revised this ADI at its 23
rd meeting (1980) after having considered some tests for mutagenicity 
in vitro, a 2-year NTP carcinogenicity study in mice, short-term toxicity studies in mice and rats, and 
more particularly a 13-week rat study performed by NTP; for all these new studies, animals were 
exposed to d-carvone in corn oil by gavage (INCHEM 718). In the latter, all rats that received 1500 
mg/kg bw/day of d-carvone died during the first week and 9/10 males and 10/10 females that received 
750 mg/kg bw/day died before the termination of the study. Final mean bodyweights of male rats that 
received 187 or 375 mg/kg bw/day were lower than those of the controls. The relative liver weights for 
dosed males and females that received 93, 187 or 375 mg/kg bw/day were increased. The relative 
kidney weights of males administered 187 or 375 mg/kg bw/day, and of females that received 375 
mg/kg bw/day were also increased. JECFA established a temporary ADI of 0-1 mg/kg bw/day for d- 
and l-carvone, based on a NOEL of 93 mg/kg bw/day and using a default uncertainty factor of 100-
fold (WHO, 1980). This ADI was then extended at the 25
th, 27
th, 30
th and 33
rd meetings. At its 37
th 
meeting  (1991),  the  Committee  determined  that  the  d-  and  l-enantiomers  should  be  evaluated 
separately.  Due  to a  lack  of  data  on l-carvone  per se,  the  temporary  ADI  for  l-carvone  was  not 
extended. During its 51
st meeting (1998), JECFA applied its Procedure for the Safety Evaluation of 
Flavouring  Agents  to  carvone  and  eight  related  substances  (WHO,  2000).  Assuming  that  all  the 
carvone consumed was d-carvone, a margin of safety >500 existed between the above-mentioned 
NOEL of 93 mg/kg bw and the daily per capita intake for d-carvone. JECFA concluded that this 
substance would not be expected to be of safety concern and maintained the ADI of 0-1 mg/kg bw/day 
previously  established  for  d-carvone.  JECFA  stated  that  the  l-enantiomer  of  carvone  would  be 
expected to share a common metabolic pathway with d-carvone. Although there were no reported 
studies with l-carvone, JECFA considered that the only material commercially available at the time of 
the original assessment (WHO, 1968) was l-carvone. On this basis, the NOEL of 125 mg/kg bw/day 
identified for carvone at the 11
th meeting would give a margin of safety >750 between this NOEL and 
the  daily  per  capita  intake  for  l-carvone,  assuming  that  all  the  carvone  intake  was  l-carvone. 
Accordingly, JECFA concluded that l-carvone would not be expected to be of safety concern at the 
levels of intake estimated at that time.  
The  Committee  for  Veterinary  Medicinal  Products  (CVMP)  of  the  European  Medicines  Agency 
evaluated  Carvi  aetheroleum  in  1998  (EMA  CVMP,  1998).  This  essential  oil  is  obtained  from 
caraway seeds and contains 45 to 65% of d-carvone. Carvi aetheroleum is used in two veterinary 
medicinal products in combination with other active principles. The CVMP used in its assessment the 
temporary ADI of 0-1 mg/kg bw for d- and l-carvone established by JECFA during its 23
rd meeting; 
the CVMP considered an intake of 1 mg/kg bw/day of d-carvone as harmless for humans. Considering 
that caraway seeds are normal components of the human diet and that the plant caraway is a normal 
component of the animal feed, and also considering that the acute and long term toxicity of Carvi Safety assessment of carvone 
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aetheroleum  is  low,  that  Carvi  aetheroleum  is  used  only  for  occasional  treatment  of  individual 
animals, and that animals are unlikely to be sent for slaughter immediately after treatment, the CVMP 
concluded that there was no need to establish a Maximal Residue Limit for Carvi aetheroleum.  
The  evaluation  of  carvone  as  a  pesticide  (sprouting  inhibitor)  was  initiated  in  1999  based  on  a 
procedure in place prior to the creation of EFSA: 
1.  An initial draft risk assessment report (DAR) was produced by a designated rapporteur 
Member State (RMS), The Netherlands, 
2.  The  RMS’s  risk  assessment  was  peer-reviewed  by  the  other  Member  States  and  the 
resulting  conclusions  were  submitted to the  European  Commission.  An  ADI  of  0.025 
mg/kg bw/day for d-carvone was established and carvone was approved to be used in the 
EU.  This  ADI  was  derived  from  a  90-day  gavage  study  with  d-carvone  in  rats 
(Schoenmakers, 1996). The treatment induced enlarged kidney and tubular necrosis in 
males,  and  increases  in  partial  thromboplastine  time  (PTT),  relative  liver  and  kidney 
weights, and significant decrease in serum albumin, Ca and thymus weights in female rats 
at doses of 30 and 180 mg/kg bw/day. After showing that the kidney pathology of male 
rats was not relevant for humans, a NOAEL was established at 5 mg/kg, derived from the 
changes in relative liver weights, the increased PTT and decreased albumin in female rats 
at 30 mg/kg bw/day and above, and using a 200-fold uncertainty factor. 
3.  The European Commission decided in 2008 to include d-carvone in the Union’s list of 
approved active substances. This allows for the substance to be used in a plant protection 
product in the EU. Decisions on the authorization of a specific product containing an 
approved active  substance  are  made  at Member  States’ level.  However,  until  now  no 
MRLs have been set for carvone due to concerns on aggregated exposure (see Background 
and section 2.1), which means that the current use of carvone in plant protection products 
is limited to those uses that do not give rise to quantifiable residues in food and feed. 
Following the creation of EFSA, the EFSA PRAS unit did some additional evaluations related to 
carvone (EFSA, 2012, 2013) but did not re-assess the ADI. These evaluations related to spearmint oil 
(RMS Sweden) and orange oil (RMS France), containing l-carvone and D-limonene, which yields 
carvone as one of its metabolites, respectively. For these oils naturally occurring in food, it was noted 
that toxicological reference values would only be needed if exposure through plant protection uses 
would exceed the estimated natural background exposure through food for humans. 
In  2009,  the  US-EPA  has  evaluated  l-carvone  as  a  repellent  for  mosquitoes  and  biting  flies  and 
concluded that the health risk for humans was expected to be minimal, based on the low oral acute 
toxicity (LD50=5400 mg/kg bw) of l-carvone (Quest International, 1986), and its long history of safe 
use as a flavouring ingredient in foods and beverages (US-EPA, 2009).  
In 2011, the FEEDAP panel of EFSA re-evaluated carvone as part of the evaluation of the safety and 
efficacy of FRESTA
® F for weaned piglets. FRESTA
® F has been defined as a preparation of partially 
micro-encapsulated essential oils from caraway and lemon, dried spices and dried herbs with carvone 
(49-59% d-carvone and 1% l-carvone in the mixture) and limonene as the marker compounds. The 
mixture  is  intended  for  use  in  weaned  piglets  at  a  recommended  dose  range  of  250–400  mg/kg 
complete  feedingstuff.  In  its  opinion,  the  FEEDAP  panel  used  the  ADI  of  0–1  mg/kg  bw/day 
identified by JECFA (EFSA FEEDAP Panel, 2011; WHO, 2000).  
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) only 
evaluated the genotoxic potential of d-carvone and l-carvone in the context of the Scientific Opinion 
on Flavouring Group Evaluation 212 Revision 1 (FGE.212Rev1). Based on the data provided by the 
flavourings industry, d-carvone [FL-no: 07.146] was found to be genotoxic in vitro; however, it was 
not carcinogenic in mice and was predicted to be non-genotoxic according to the four MultiCASE Safety assessment of carvone 
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models  used  for  a  (quantitative)  structure-activity  relationship  (Q)SAR  prediction  of  d-carvone’s 
genotoxicity (while it was out of domain in the ISS model) . Therefore, the CEF Panel concluded that 
d-carvone, together with l-carvone, the structurally related carveol and its esters could be evaluated 
using the “Procedure” as applied by JECFA (EFSA CEF Panel, 2011a). The carvone enantiomers had 
been  evaluated  by  JECFA  before  2000  (WHO,  2000);  therefore,  in  line  with  the  provisions  of 
Regulation (EC) No 1565/2000 (EC, 2000) no re-evaluation of the flavouring substance by EFSA was 
required. 
From the recent ECHA assessment, no classification for acute toxicity was required for carvone but it 
was classified as a skin irritant with Xi and R38 as category 2 irritant (H315) as well as a  skin 
sensitiser Cat1B: H317 according to the Classification Labelling and Packaging (CLP) regulation. It 
was not classified as a corrosive substance, or as an eye or respiratory tract irritant in either the CLP 
Regulation or the Dangerous Substance Directive (DSD) (ECHA, 2013). Based on the assessment of 
the  non-lethal  adverse  effects  caused  by  carvone  in  the  acute  oral  and  inhalation  studies,  ECHA 
concluded that carvone does not have specific target organ toxicity (ECHA, 2013).  
2.  INTERPRETATION OF THE TERMS OF REFERENCE 
In view of the previous evaluations of carvone (see section 1.8) and the indication of a lack of toxicity 
data for l-carvone, the Scientific Committee decided to consider d- and l-carvone separately for the 
hazard  and  exposure  assessment.  The  second  and  third  points  of  the  Terms  of  Reference,  i.e. 
estimating the overall exposure of European consumers to carvone, and the contribution of the various 
sources of exposure to the overall exposure to carvone will be addressed as requested in the mandate.  
In view of an expected request for extending the application of d-carvone as a pesticide to ware and 
starch potatoes; the Scientific Committee decided to include this use in its assessment.  
3.  DATA AND METHODOLOGIES  
3.1.  Data  
3.1.1.  Data sources used for the hazard assessment 
The Scientific Committee used the previous safety assessments of carvone (see section 1.8) as the 
primary source of information. The various assessment reports (US-EPA, 2009; EFSA CEF Panel, 
2011a; EFSA, 2012; ECHA, 2013, WHO Food Additives Series on carvone, and the Draft Assessment 
Report (DAR) of the Rapporteur Member State in charge of the evaluation of carvone as a pesticide 
active  substance)  were  collected.  The  key  studies  driving  the  hazard  assessment,  i.e.  the  studies 
provided  by  the  data-owner  who  applied  for  the  authorisation  of  carvone  as  a  pesticide  active 
substances, and the NTP studies used by JECFA were retrieved and re-evaluated by the Scientific 
Committee (See section 4.2.2 for a description of these studies). 
For the hazard identification and characterisation of d- and l-carvone, extensive literature searches 
were performed in Pubmed (1966-current) and Web-of-Knowledge (1970-current) in June 2013 and 
on a monthly basis (until May 2014) to retrieve experimental in vitro and in vivo studies on the 
metabolism, toxicokinetics and toxicity for d- and l-carvone in test species (dog, rat, mice, rabbit) and 
humans using the following key words: 
-[carvone] and [metabolism] and [rat]/ [dog]/ [rabbit]/ [mice]/ [rabbit]/ [human] 
-[carvone] and [pharmacokinetics]/[toxicokinetics] and [rat]/ [dog]/ [rabbit]/ [mice]/ [rabbit]/ [human] 
-[carvone] and [toxicity]/[toxicology] and [rat]/ [dog]/ [rabbit]/ [mice]/ [rabbit]/ [human] 
In addition, references in the grey literature from previous pharmacokinetic/toxicokinetic/toxicological 
studies and risk assessments performed by international bodies (EFSA, JECFA, US-EPA, ECHA, Safety assessment of carvone 
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NTP) were also searched to screen for other relevant experimental in vitro and in vivo studies that may 
have been missed from the pubmed searches.  
The results of these extensive literature searches on the toxicokinetics and toxicity of d- and l-carvone 
were reviewed by the working group and datagaps were also identified. These are summarised in the. 
section  4.2  (hazard  identification  and  characterisation)  and  key  datagaps  are  highlighted  in  the 
uncertainty analysis part of the document (section 4.4). 
3.1.2.  Data sources used for the exposure assessment 
3.1.2.1.  Food consumption data 
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database), built 
from the most recent national dietary surveys in EU members states, contains national information on 
food consumption at the level of individual subjects. High percentiles of exposure were only reported 
for  those  foods  and  population  groups  where  the  sample  size  was  sufficiently  large  to  allow 
calculation of the 95
th percentile. The food consumption data gathered at EFSA were collected by 
different methodologies and thus direct country-to-country comparison should be made with caution. 
Consumption records were codified according to the FoodEx classification system. (EFSA, 2011a).  
3.1.2.2.  Daily exposure to orally-used personal care products 
Daily exposure levels for different cosmetic product types (toothpaste and mouthwash) were taken 
from the distribution of measured values (Hall et al., 2007, 2011). 
3.1.2.3.  Food and non food concentration data  
Data on d- and l-carvone occurrence in natural food sources were retrieved from published data from 
VCF  (Volatile  Compounds  in  Food),  a  database  compiled  from  literature  by  the  Netherlands 
Organisation for Applied Scientific Research (TNO), as well as data on the contents of carvone in 
foods from  other  publications.  Additional  data  were  provided  in  February  2014  by  the  European 
Herbal Infusions Association (EHIA) on the content of l-carvone in spearmint (dry product) used for 
herbal infusions.  
The data reported by EHIA show similar levels of l-carvone in dry leaves of Mentha spicata (9000 
mg/kg) as those described by Ravid et al. in 1987 (7000 mg/kg; see Table 3). EHIA has also reported a 
transfer rate of 40% of l-carvone from spearmint leaves into the tea beverage upon hot water infusion. 
This  information  was  taken  into  account  to  estimate  the  exposure  to  carvone  resulting  from  the 
consumption of tea and herbal infusions reported in the EFSA comprehensive database. 
Data on d- and l-carvone occurrence from their use as flavouring substances were provided to EFSA 
for the purpose of its safety assessment by the European Flavour and Fragrance Association (EFFA) in 
January 2014. 
l-Carvone residue data from supervised field trials on potatoes resulting from the use of spearmint oil 
as a sprouting inhibitor were provided in the course of the peer-review of the use of spearmint oil 
(EFSA 2012). Supervised field trial data give an indication of the residues that can be expected under 
Good Agricultural Practices (GAP). 
Anticipated d-carvone occurrence data from its intended use as a sprouting inhibitor on ware and 
starch potatoes were retrieved from supervised field trial data present in the pesticide authorisation 
dossier from the original application in 1999. Safety assessment of carvone 
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d-Carvone occurrence data from its use as a feed additive were retrieved from the scientific opinion of 
the EFSA FEEDAP Panel  on the safety and efficacy  of FRESTA
®  F  for  weaned  piglets  (EFSA 
FEEDAP Panel, 2011).  
d-Carvone occurrence data from veterinary use were retrieved from the assessment performed by the 
Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA 
CVMP, 1998). Two veterinary medicinal products contain the volatile oil of Carvi aetheroleum in 
combination with other active principles. The first product contains 0.004% of Carvi aetheroleum; it is 
used as a nose-spray to facilitate breathing in new-born animals (all food-producing species), which 
results in a maximal dose of 0.012g of Carvi aetheroleum. The second product contains 1% of Carvi 
aetheroleum and is prescribed for treatment of flatulence and disturbances of the stomach and the gut 
in cattle, horse, pigs, sheep and goats, The maximal dose corresponds to 0.15g of Carvi aetheroleum.  
Carvi aetheroleum and carvi fructus are registered as Herbal Medicinal Products by the European 
Medicines  Agency  (EMA).  On  15  June  2012,  EMA  published  a  call  for  data  to  be  used  in  the 
assessment of Carum carvi L., aetheroleum and fructus, as part of the establishment of Community 
herbal monographs and/or Community list entries. At the date of the adoption of this opinion, EMA’s 
assessment  of  carvi  aetheroleum  and  carvi  fructus  was  not  finalised,  and  the  EFSA  Scientific 
Committee had no knowledge of occurrence data to assess the exposure to d-carvone from medicinal 
use. 
Data on d- and l-carvone occurrence in personal care products were described for toothpaste in the 
exposure assessment of the DAR (addendum vol.3 annex B April 2005) and for mouthwash from 
several internet sources (Lioka et al., 1984; Sato et al., 1984) 
3.2.  Methodologies 
3.2.1.  Hazard Assessment 
Critical endpoints were selected based on expert judgement
3 and statistical significance criteria. The 
recommendations of the EFSA Scientific Committee opinion on statistical significance and biological 
relevance (2011) were followed. 
A dose-response modelling of the critical endpoints was then performed using the EFSA guidance on 
benchmark dose modelling (EFSA Scientific Committee, 2009a). PROAST version 40.7 was used in 
the analyses (www.proast.nl). See Appendix C for further details.  
3.2.2.  Exposure Assessment 
The Scientific Committee noted that different procedures and models are used in the assessment of 
dietary exposure to chemical substances in the remit of EFSA’s Panels (e.g. EFSA PRIMo model
10 to 
assess the short-term (acute) and long-term (chronic) exposure of consumers to pesticide residues ) 
(EFSA, 2011b). These differences are due to the different assumptions made to compensate for the 
lack of food consumption (e.g. use of aggregated data or intake models) and occurrence data (e.g. use 
of maximum concentration or average concentration) in relation to the specific requirements of  the 
substances under the evaluation remit of the EFSA Panels.  
Considering that large uncertainties could arise from conserv ative estimates of exposure to carvone 
using the models of the relevant Panels, the Scientific Committee decided to estimate exposure to l- or 
d-carvone separately from each individual source which  may  appear  in  food  (pesticides,  flavouring  
                                                       
10 See http://www.efsa.europa.eu/en/mrls/mrlteam.htm  Safety assessment of carvone 
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substances,  feed,  natural  occurrence).  Food  consumption  data  from  the  EFSA  Comprehensive 
European  Food  Consumption  Database  (Comprehensive  Database)  were  used  in  the  exposure 
assessment of carvone.  
The Scientific Committee estimated chronic exposure for the following population groups: toddlers, 
children,  adolescents,  adults  and  the  elderly.  Calculations  were  performed  using  individual  body 
weights.  
For the present assessment, food consumption data were available from 26 different dietary surveys 
carried out in 17 different European countries, as mentioned in Table 2.  
Table 2:   Population groups considered for the exposure estimates of carvone 
Population  Age range  Countries with food consumption surveys 
covering more than one day 
Toddlers  from 12 up to and including 35 
months of age 
Belgium,  Bulgaria,  Finland,  Germany,  Italy, 
Netherlands, Spain 
Children
11  36 months up to and including 9 
years of age  
Belgium,  Bulgaria,  Czech  Republic,  Denmark, 
Finland,  France,  Germany,  Greece,  Italy,  Latvia, 
Netherlands, Spain, Sweden  
Adolescents  from 10 up to and including 17 
years of age  
Belgium,  Cyprus,  Czech  Republic,  Denmark, 
France, Germany, Italy, Latvia, Spain, Sweden 
Adults  from 18 up to and including 64 
years of age 
Belgium,  Czech  Republic,  Denmark,  Finland, 
France, Germany, Hungary, Ireland, Italy, Latvia, 
Netherlands, Spain, Sweden, UK  
The elderly
11   older than 65 years  Belgium,  Denmark,  Finland,  France,  Germany, 
Hungary, Italy 
 
Mean and 95th percentile of exposure were calculated using the raw individual food consumption data 
at the individual level  according to the finest level of detail available in the FoodEx classification 
system  (i.e.  FoodEx  4)  with  the  median  concentration  data  (pesticides,  flavouring)  or  average 
concentration data (natural occurrence, feed) of d- and l-carvone reported from industries or literature 
sources. 
For personal care products i.e mouthwash and toothpaste, the estimated adult daily exposure levels 
have been calculated by the Scientific Committee using the daily amounts applied in average and at a 
95th percentile from the distribution of measured  values (Hall et al., 2007, 2011) with the average 
concentration data of d and l-carvone. The Scientific Committee also looked at different non-food 
sources of carvone, such as dermal exposure from cosmetics and personal care products. However, 
information  on  the  likely  uptake  of  carvone  through  the  dermal  route,  and  the  subsequent 
biokinetics/biotransformation in the body is currently limited. The Scientific Committee therefore 
considered that it would be difficult to integrate the different routes into aggregated exposure, and 
decided to focus only on those carvone-containing non-food products that might lead to an oral intake. 
Thus, whilst there is a possibility for additional sources of carvone exposure through dermal and/or 
inhalation routes, this opinion has only considered the two main applications in personal care products 
that are likely to lead to oral intake, i.e.  mouthwash and toothpaste, in the estimation of aggregated 
exposure.  
The same methodology has been applied for the aggregated exposure to d- and l-carvone taking into 
consideration each individual sources for each enantiomer. The calculation has been performed by the 
                                                       
11 The terms ‘children’ and ‘the elderly’ correspond respectively to ‘other children’ and the merger of ‘elderly’ and ‘very 
elderly’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in 
Exposure Assessment’ (EFSA, 2011a). Safety assessment of carvone 
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EFSA DATA unit, using the raw food consumption data at the individual level according to the finest 
level of detail available in the FoodEx classification system (i.e. FoodEx 4). The median concentration 
data (pesticides, flavouring) or average concentration data (natural occurrence, feed) for d- and l-
carvone reported by the industry or in the literature for each food sources were used. For each subject, 
exposure estimates derived from the use of personal care products were added to those estimated from 
the diet. For each individual exposure source and for the aggregated estimates, a distribution has been 
obtained for the five population groups and expressed as a range (min-max) for the average and high 
levels (P95 consumers).  
For  the  aggregated  exposure,  the  Scientific  Committee  has  performed  six  exposure  scenarios  to 
differentiate estimated exposures to d or l-carvone due to current uses from exposure expected from 
intended pesticide uses, and to take into account the uncertainties arising from the unspecified form of 
carvone  from  natural  food  occurrence  or  from  the  lack  of  detailed  information  in  the  food 
consumption database concerning the type of species of tea or herbs used for the preparation of tea and 
herbal infusions (Table 9). 
Scenario 1 corresponds to the aggregated oral exposure to d-carvone from current uses (feed additive, 
pesticides uses, flavourings, natural food occurrence, personal care products). All individual exposures 
sources  are  described  in  detail  in  Table  7  and  the  contribution  of  all  sources  to  this  aggregated 
exposure expressed in average is described in Table 10. 
Scenario 2 corresponds to the aggregated oral exposure to d-carvone from current uses (feed additive, 
pesticides  uses,  flavourings,  natural  food  occurrence,  personal  care  products)  plus  the  intended 
pesticides uses on ware and starch products. Exposure from this additional use is described in detail in 
Table 7 and the contribution of this use, expressed in average, to the aggregated exposure is described 
in Table 10. 
Scenario 4 corresponds to the aggregated oral exposure to l-carvone from current uses (spearmint oil 
as pesticide, flavourings, natural food occurrence, personal care products). All individual exposures 
sources  are  described  in  detail  in  Table  8  and  the  contribution  of  all  sources  to  this  aggregated 
exposure, expressed in average, is described in Table 11. 
The last 3 scenarios address the uncertainties arising from: 
  the unspecified form of carvone reported in some of the natural food occurrence data. These 
data are considered as d-carvone in Scenario 3, and l-carvone in Scenario 5.  
  the lack of detailed information on the types of tea or herbal infusions reported in the food 
consumption database. This aspect is addressed in Scenario 6: 100% of the tea/herbal solid 
and liquid infusions are considered as Mentha spicata (in the form of l-carvone).  
The outputs of these last 3 scenarios were not presented in detail in the  exposure Tables but are 
discussed in the text. 
3.2.3.  Characterisation of uncertainty 
The uncertainties related to this safety assessment of carvone were characterised, using the approaches 
described in the guidance of the Scientific Committee related to uncertainties in dietary exposure 
assessment  (EFSA  Scientific  Committee,  2006)  and  in  line  with  the  principles  described  in  the 
guidance of the Scientific Committee on transparency in scientific aspects of risk assessments carried 
out  by  EFSA  –  Part  2:  general  principles  (EFSA  Scientific  Committee,  2009b).  The  report  on 
“Characterizing and Communicating Uncertainty in Exposure Assessment” (WHO/IPCS, 2008) was 
considered when drafting section 4.4.  Safety assessment of carvone 
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4.  ASSESSMENT 
4.1.  Human exposure assessment 
The Scientific Committee agreed to consider all possible routes of oral exposure (see section 1.6).  
The Scientific Committee noted the potential role of d-limonene, present in food from the use of 
orange oil as an insecticide on tomato and courgette, from its use as a food flavouring substance or 
from its natural food occurrence, as a precursor of carvone. As summarised in the CEF opinion on 
flavouring  group  evaluation  25  (EFSA  CEF  Panel,  2011b)  and  as  explained  in  section  4.2.1.3, 
limonene is not converted to carvone but to carveol which is then rapidly excreted. Based on this 
information, the Scientific Committee concluded that limonene does not need to be taken into account 
as an additional source of exposure to carvone. 
Considering the terms of reference of this opinion specifically requiring to review the ADI of carvone, 
and the toxicological profile of carvone with the absence of acute toxicity (see section 4.2.2.1), the 
Scientific  Committee  concluded  that  it  was  appropriate  to  base  the  safety  assessment  on  chronic 
exposure to carvone. 
The Scientific Committee noted that both carvone enantiomers occur naturally. For some foods, the 
naturally occurring configurations are known; for example, d-carvone occurs in caraway and dill and 
l-carvone occurs in spearmint. For other foods, the configuration has not been specified. Therefore, the 
Scientific Committee considered several scenarios in order to give exposure figures for both l- and d-
enantiomers, but also to characterise uncertainties arising from the reported unspecified forms. 
All the results for the estimated individual exposure source to d- or l- carvone and from the aggregated 
scenarios are presented in Tables 7 to 11. As mentioned before, the use of these various scenarios will 
also allow for the quantification of the uncertainties associated with the exposure assessment. 
4.1.1.  Estimated exposure to d- and l-carvone from natural food occurrence 
The Scientific Committee noted that carvone may be present in foods including fruits, fruit juices, 
leaves and seeds at different concentration levels ranging from below 0.2 mg/kg in fruit and fruit 
juices  such  as  mandarin, grapefruit,  guava  and  orange  to  high  concentrations  up  to  20000-30000 
mg/kg predominantly in caraway and dill seeds (Table 3).  
Exposure to carvone has been estimated by the Scientific Committee using the raw individual food 
consumption data at the most detailed level from the EFSA food Comprehensive Database (EFSA, 
2011a) in combination with the mean carvone concentration value (d- and l- enantiomer) reported in 
Appendix  D.  Mean  composition  values  have  been  calculated  for  the  purpose  of  estimating  the 
background chronic intake of carvone from natural food occurrences, with the assumption that the 
distribution of the composition data per category follows a uniform distribution (when a range is 
expressed).  Safety assessment of carvone 
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Table 3:   Compositional data for carvone from natural food sources  
Food  Configuration  TNO VCF 
(ppm)
(a) 
Content of 
oil (%)
(b) 
Content of 
carvone in 
oil (%)
(b) 
Content of 
carvone in 
food (mg/kg)
(c) 
Reference  Mean content of 
carvone in food 
(mg/kg) 
Caraway 
(seeds) 
  
  
  
d-carvone 
  
  
  
512000  3.6  51.2  18432  Ravid et al. 1987   
 
 
 
26800 
480000-
560000 
5.65  53.7  30340  Hälvä et al. 1986 
   7.02  52  36504  Hälva et al. 1986 
   6.74  49.7  33498  Hälva et al 1986 
Dill (seeds) 
  
d-carvone     3.8  59.3  22534  Ravid et al. 1987 
   -  -  19500  Blank and Grosch 1991 
Dill (herbs)  d-carvone    0.2-2.5  0.4-50    Teuscher et al., 2005  3250 
Cinnamonum 
osmophhloeum 
Kanehira 
Bark 
Leaves 
d-carvone       
  
  
0.16 
0.88 
  
  
  
0.21 
0.05 
  
  
  
3.4 
4.4 
Fang et al. 1989  3.4 
(only  bark  value 
considered  as 
relevant) 
Mentha spicata 
L. (leaves) 
 
 
l-carvone 
 
699000  1.0  69.9  6990  Ravid et al. 1987 
 
8083 
(considering  a 
transition  rate  from 
dry  product  to 
infusion  ready  to 
drink  of  40%  gives 
an  estimation  of 
32.33  mg/L  of  l-
carvone  in  ready-to-
drink infusions) 
   1.24  74  9176  EHIA, 2014 
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Food  Configuration  TNO VCF 
(ppm)
(a) 
Content of 
oil (%)
(b) 
Content of 
carvone in 
oil (%)
(b) 
Content of 
carvone in 
food (mg/kg)
(c) 
Reference  Mean content of 
carvone in food 
(mg/kg) 
Orange juice  Not specified  trace – 0.110        trace – 0.110  Moshonas  and  Shaw 
1994 
0.055 
Orange juice  racemic        156 - 210  Averbeck and 
Schieberle 2009 
0.192 
Grapefruit 
juice 
Not specified  0 – 0.057        n.d. – 0.057  Shaw et al. 2000  0.029 
Mandarin 
juice 
Not specified  6        0.006 – 0.023  Pérez et al. 2005  0.015 
Mandarins 
(fruits) 
Not specified  0.117        0.045 – 0.116  Tietel et al. 2010  0.08 
Guava (fruits)  Not specified  0.01 -0.05        0.01 – 0.05  Idstein  and  Schreier 
1985 
0.03 
Anise 
(Pimpinella 
ansium) 
(seed) 
(whole plant) 
  
  
Not specified 
  
  
  
  
  
  
3000 
  
  
  
  
1.1 
1.35 
  
  
  
0.3 
2.1 
  
  
  
33 
284 
Embong et al. 1977  158 
Celery 
(stem  and 
leaves) 
Not specified  0.05        0.05  MacLeod et al. 1988    
0.05 
Rosemary 
(leaves) 
Not specified  2600  1.03  0.26  27  Reverchon and Senatore 
1992 
27 
  
(a):  Quantities as reported in the database VCF Volatile Compounds in Foods (version 14.1) 
(b):  Contents according to the respective reference 
(c):  Contents calculated on the basis of the contents of oil and the contents of carvone in the oil according to the respective reference 
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Based on this approach: 
  the  estimated  exposures  to  d-carvone  from  natural  food  sources  in  the  young  population 
(including toddlers, children and adolescents) range from <0.0001 mg/kg bw/d up to 0.13 
mg/kg bw/d in average and from <0.0001 mg/kg bw/d up to 0.43 mg/kg bw/day in high 
consumers. For the adult population (including the elderly), the estimated exposures range 
from <0.0001 mg/kg bw/d up to 0.07 mg/kg bw/d in average and from <0.0001 mg/kg bw/d 
up to 0.21 mg/kg bw/day in high consumers (Table 7). The main food groups contributing to 
the overall exposure to d-carvone (>10%) are herbs, spices and condiments 
  the estimated exposure to l-carvone from natural food sources in the five population groups is 
up to 0.0003 mg/kg bw/day, including high consumers (Tables 8).  
4.1.2.  Estimated exposure to d- and l-carvone from their use as flavouring substances 
As mentioned earlier and for harmonising the estimated exposure calculations made for the various 
food sources, the Scientific Committee decided to use the same level of description of the EFSA 
comprehensive database (level 4) in combination with the medians of the normal concentration levels 
of the food uses reported by the Industry. 
Medians from normal and maximum use levels of d and l-carvone were provided to EFSA for the 
purpose  of  its  safety  assessment  by  the  European  Flavour  and  Fragrance  Association  (EFFA)  in 
January 2014 (Tables 4 and 5). 
These data were used to estimate exposures in line with the safety evaluation program of flavouring 
compounds done by the EFSA CEF Panel, which is based on the normal added use levels in the 
potentially  flavoured  foods  and  beverages  corresponding  to  the  18  food  categories  as outlined  in 
Annex III of the Commission Regulation (EC) N° 1565/2000 (EC, 2000) and reported by the flavour 
Industry in the way described in Tables 4 and 5 below. 
Table 4:   Medians of the normal and maximum use levels (ULs) (mg/kg) for d-carvone provided by 
EFFA in 2014 
  Category  Normal   Maximum 
01.0  Dairy products, excluding products of category 02.0  2.6  3.3 
02.0  Fats and oil, and fat emulsions (type water-in-oil)  4.4  12.5 
03.0  Edible ices, including sherbet and sorbet  2.0  10.0 
04.1  Fruit  0.0  0.1 
05.0  Confectionery  5.2  1.7 
06.0  Cereals and cereal products, incl. flours & starches  
from roots & tubers, pulses & legumes, excluding 
bakery 
0.0  0.1 
07.0  Bakery wares  0.8  1.4 
08.0  Meat and meat products, including poultry and game  13.8  56.3 
09.0  Fish and fish products, including molluscs, crustaceans 
and echinoderms (MCE) 
20.0  100 
10.0  Eggs and egg products  2.0  20.0 
11.0  Sweeteners, including honey  2.0  20.0 
12.0  Salts, spices, soups, salads, protein products, etc.  0.2  2.4 
13.0  Foodstuffs intended for particular nutritional uses  -  - 
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  Category  Normal   Maximum 
14.1  Non-alcoholic (“soft”) beverages  2.5  2.2 
14.2  Alcoholic beverages, incl. alcohol-free and low-
alcoholic counterparts 
20.0  100 
15.0  Ready-to-eat savouries  20.0  135 
16.0  Composite foods (e.g. casseroles, meat pies, 
mincemeat) – foods that could not be placed in 
categories 01.0 – 15.0 
-  - 
5.3  Chewing gum  200  1360 
 
Values in bold indicate that normal ULs and not max ULs data were provided by one of the four companies. As a result, the 
median of the max ULs may be lower than the median of the normal ULs. In such a case, the highest value (i.e. the 
normal ULs) was used for the exposure assessment. 
Table 5:   Medians of the normal and maximum use levels (ULs) (mg/kg) for l-carvone provided by 
EFFA in 2014 
  Category  Normal   Maximum 
01.0  Dairy products, excluding products of category 02.0  1.6  20.1 
02.0  Fats and oil, and fat emulsions (type water-in-oil)  0.5  2.3 
03.0  Edible ices, including sherbet and sorbet  50  267 
04.1  Fruit  -  - 
05.0  Confectionery  2.0  250 
06.0  Cereals and cereal products, incl. flours & starches  
from roots & tubers, pulses & legumes, excluding 
bakery 
2.8  13.4 
07.0  Bakery wares  4  10 
08.0  Meat and meat products, including poultry and game  -  - 
09.0  Fish and fish products, including molluscs, crustaceans 
and echinoderms (MCE) 
-  - 
10.0  Eggs and egg products  -  - 
11.0  Sweeteners, including honey  5.0  20.0 
12.0  Salts, spices, soups, salads, protein products, etc.  0.2  0.5 
13.0  Foodstuffs intended for particular nutritional uses  -  - 
14.1  Non-alcoholic (“soft”) beverages  27.4  102.5 
14.2  Alcoholic beverages, incl. alcohol-free and low-
alcoholic counterparts 
50  20 
15.0  Ready-to-eat savouries  0.2  0.4 
16.0  Composite foods (e.g. casseroles, meat pies, 
mincemeat) – foods that could not be placed in 
categories 01.0 – 15.0 
-  - 
5.3  Chewing gum  1353  7170 
 
Values in bold indicate that normal ULs and not max ULs data were provided by one of the four companies. As a result, the 
median of the max ULs may be lower than the median of the normal ULs. In such a case, the highest value (i.e. the 
normal ULs) was used for the exposure assessment. 
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Based on this approach: 
  the  use  of  d-carvone  as  a  flavouring  substance  leads  in  the  young  population  (including 
toddlers, children and adolescents) to estimated exposures ranging from 0.04 mg/kg bw/d up 
to 0.17 mg/kg bw/d in average and from 0.08 mg/kg bw/d up to 0.41 mg/kg bw/day in high 
consumers. For the adult population (including the elderly), the estimated exposures range 
from 0.04 mg/kg bw/d up to 0.15 mg/kg bw/d in average and from 0.12 mg/kg bw/d up to 0.50 
mg/kg bw/day in high consumers (Table 7). The main food groups contributing to the overall 
exposure to d-carvone (>10%) are meat and meat products, milk and dairy products, fish and 
other seafood, alcoholic and non-alcoholic beverages 
  the  use  of  l-carvone  as  a  flavouring  substance  leads  in  the  young  population  (including 
toddlers, children and adolescents) to estimated expoures ranging from 0.02 mg/kg bw/d up to 
0.25 mg/kg bw/d in average and from 0.07 mg/kg bw/d up to 0.67 mg/kg bw/day in high 
consumers. For the adult population (including the elderly), the estimated exposures range 
from 0.05 mg/kg bw/d up to 0.30 mg/kg bw/d in average and from 0.21 mg/kg bw/d up to 1.15 
mg/kg bw/day in high consumers (Table 8). The main food groups contributing to the overall 
exposure to l-carvone (>10%) are milk and dairy products, snacks and desserts and alcoholic 
and non-alcoholic beverages. 
4.1.3.  Estimated exposure to d-carvone from its use as a pesticide 
Currently, d-carvone is only authorised as an anti-sprouting substance for seed potatoes; it may not be 
used  on  ware  and  starch  potatoes.  No  residues  of  carvone  are  expected  on potatoes  grown  from 
carvone-treated seed potatoes. 
In the framework of national enforcement and monitoring of pesticide residues, carvone was only 
analysed in 2009. 1316 food samples were monitored covering different commodities (about sixty 
samples were potatoes); none of these samples contained residues of carvone above  the Limit of 
Quantification (LOQ=0.01 mg/kg) (EFSA, 2011c) 
The Scientific Committee concluded that the exposure to d-carvone from its authorised use as anti-
sprouting agent on seed potatoes is negligible (Table 7). 
4.1.4.  Estimated exposure to l-carvone from the use of spearmint oil as a pesticide  
Use of spearmint oil
12 as plant growth regulator for postharvest treatment of potatoes can lead to 
residues of l-carvone up to 2 mg/kg, as shown by the residue data provided in the course of the peer-
review of the use of spearmint oil (EFSA, 2012):  
  Waiting period (WP) 0 days; analyte l-carvone  1.11, 1.19, 1.84 mg/kg  
  Waiting period 7+1 days; analyte l-carvone  0.56, 0.57, 2x 0.93, 1.22, 1.49 mg/kg 
 
The  Scientific  Committee  notes that  there is  not  yet  an  agreement  on the  residue  definition  (see 
Glossary), and that the waiting period is not specified in the proposed Good Agricultural Practices. For 
the exposure assessment, the Scientific Committee decided to use the median residue found in the 
trials with WP 0 days (i.e. 1.19 mg/kg, rounded to 1.2 mg/kg) in combination with all potatoes and 
potato- based products reported in the EFSA Comprehensive European Food Consumption Database 
(Appendix D). 
                                                       
12 Spearmint oil contains l-carvone Safety assessment of carvone 
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In the Draft Assessment Report (DAR) on carvone, it is concluded that following the use of carvone as 
a pesticide, >90% of the carvone residue resides on the potato peel. Processing studies reported in the 
DAR  indicate  that  further  processing  like  cooking  or  roasting  does  not  much  influence  the  residue  level. 
Although potatoes are never eaten raw, unpeeled potatoes are sometimes consumed; there is however 
no data on to what extent. The residue levels for unpeeled raw potatoes are therefore used in the exposure 
assessment.  
The estimated exposure to l-carvone from the use of spearmint oil on potatoes in the young population 
(including toddlers, children and adolescents) ranges from 0.001 mg/kg bw/d up to 0.009 mg/kg bw/d 
in average and from 0.004 mg/kg bw/d up to 0.02 mg/kg bw/day in high consumers. For the adult 
population (including the elderly), the estimates range from 0.001 mg/kg bw/d up to 0.004 mg/kg bw/d 
in average and from 0.003 mg/kg bw/d up to 0.01 mg/kg bw/day in high consumers (Table 8). 
The Scientific Committee considers these estimates as conservative because they are based on the 
assumption that all potatoes and potato-based products are consumed unpeeled with no processing 
factors taken into account for cooking and with no ingredients factors taken into account for composite 
foods. 
4.1.5.  Anticipated  exposure  to  d-carvone  from  its  intended  use  as  a  pesticide  (sprouting 
inhibitor) on ware and starch potatoes  
d-Carvone is currently authorized for use as a sprouting inhibitor on seed potatoes only. If d-carvone 
would also be used at the same levels on ware and starch potatoes (see section 2), this would result in 
detectable residues. The pesticide authorisation dossier from the original application in 1999 contains 
supervised residue trial data that give an indication of the residues that can be expected (see Table 6). 
For the current assessment and as explained earlier, the Scientific Committee decided to use the EFSA 
Comprehensive European Food Consumption Database in order to better integrate the exposure from 
all other sources. Residue trial data from the DAR (Table 6) are used to estimate the residue levels that 
European consumers could be exposed to. 
Table 6:   Summary of critical residues data (DAR) 
Crop  Northern 
(N) or 
Mediter-
ranean (S) 
Region 
Trials  results 
relevant  to  the 
critical  GAP 
(mg/kg) 
Recommendation 
/comments 
MRL 
(mg/kg) 
STMR 
(mg/kg) 
HR 
(mg/kg) 
potato  N  1x 1.4, 1x 2.0, 
1x 3.6, 1x 3.9, 
1x 4.0, 1x 4.6, 
1x 5.9 
GAP:  total  600  ml 
product  /  1000  kg 
potatoes;  waiting 
period  2-3  weeks 
after  last  application; 
Bintje  variety  as 
worst case 
10 
(provisional) 
3.9 
(provisional) 
5.9 
(provisional) 
MRL = Maximum Residue Limit, STMR = Supervised Trial Median Residue, HR = Highest Residue 
 
To estimate the exposure from this intended use, and according to the current EFSA pesticides risk 
assessment procedure, the Scientific Committee decided to use the Supervised Trials Median Residue 
- STMR (3.9 mg/kg) in combination with the consumption of all potatoes and potato-based products 
listed in the EFSA Comprehensive European Food Consumption Database (Appendix D). Safety assessment of carvone 
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The anticipated use of d-carvone on ware and starch potatoes would lead in the young population 
(including toddlers, children and adolescents) to estimated exposures ranging from 0.004 mg/kg bw/d 
up to 0.03 mg/kg bw/d in average and from 0.01 mg/kg bw/d up to 0.07 mg/kg bw/day  in high 
consumers. For the adult population (including the ederly), the estimated exposure would range from 
0.003 mg/kg bw/d up to 0.01 mg/kg bw/d in average and from 0.009 mg/kg bw/d up to 0.03 mg/kg 
bw/day in high consumers (Table 7).  
The  Scientific  Committee  notes  the  conservative  assumption  that  all  potatoes  and  potato-based 
products are consumed unpeeled with no processing factors taken into account for cooking and with 
no ingredients factors taken into account for composite foods.  On the other hand, the absence of 
residue trials at a 0-day waiting period could lead to an underestimation of the residue levels on the 
treated ware and starch potatoes.  
4.1.6.  Estimated exposure to d-carvone from its use as a feed additive  
A scientific opinion on the safety and efficacy of FRESTA
® F for weaned piglets was made available 
by the EFSA Panel on additives and products or substances used in animal feed (EFSA FEEDAP 
Panel, 2011). FRESTA
® F is a preparation of partially micro-encapsulated essential oils from caraway 
and lemon, dried spices and dried herbs. No residues of d-carvone could be detected in meat sample 
analyses (LOD of 0.04 mg/kg). The Scientific Committee estimated the exposure taking into account 
an upperbound scenario (EFSA, 2010), i.e. the LOD is used as the residue level in pork meat from 
weaned piglets fed with FRESTA
® F in combination with the consumption of all pork-based products 
listed in the EFSA Comprehensive European Food Consumption Database (Appendix D). 
The estimated exposure to d-carvone in all populations groups would  be <0.0001 mg/kg bw/d in 
average and <0.0002 mg/kg bw/day in high consumers (Table 7), i.e. can be considered as negligible. 
4.1.7.  Estimated exposure to d-carvone from veterinary and medicinal use 
Based on the d-carvone content data of existing veterinary medicinal product (see section 3.1.2), and 
the fact that these products are used only for occasional treatment of individual animals, which are 
unlikely to be sent for slaughter immediately after treatment, the Scientific Committee concluded that 
the exposure to d-carvone from the reported veterinary use is negligible.  
In  the  absence  of  data  on  the  use  of  Carum  carvi  in  herbal  medicinal  products,  the  Scientific 
Committee was unable to assess the exposure to d-carvone from medicinal use. 
4.1.8.  Estimated exposure to d- and l-carvone from orally-used personal care products 
Apart  from  food  related  uses,  d-  and  l-carvone  are also  used  in  a  variety  of non-food  consumer 
products, including cosmetics and personal care products (toothpaste and mouthwash).  
The carvone content in toothpaste is described in the exposure assessment of the DAR (addendum 
vol.3 annex B April 2005) with 3-10% spearmint oil (80% l-carvone) which corresponds to an average 
content of 52000 mg l-carvone/kg toothpaste + 1-2% dill or caraway oil (60% d-carvone) which 
corresponds to an average content of 9000 mg d-carvone/kg toothpaste.  
The carvone content in mouthwash is described in several internet sources and estimated to be 1.5% l-
carvone, which corresponds to 15000 mg l-carvone/kg mouthwash. Safety assessment of carvone 
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The adult daily exposure levels for different cosmetic product types have been  estimated by the EC 
Scientific Committee on Consumer Safety (EC SCCS, 2012) using data provided for several product 
types including toothpaste in 2005 and mouthwash in 2009 (Hall et al. 2007, 2011). These values take 
into account the daily amount resulting from oral exposure. In order to provide a pertinent prediction 
for the European population, the exposure data for these types  of products were generated using 
probabilistic analysis. The daily amounts applied in average and at a 95th percentile were taken from 
the distribution of measured  values (Hall et al.,  2007, 2011).  For toothpaste, the estimated daily 
exposure is 1.5 mg/kg bw/day in average and 2.4 mg/kg bw/d at the 95th percentile. For mouthwash, 
the estimated daily exposure is 18.3 mg/kg bw/day in average and 42.1 mg/kg bw/d at the 95th 
percentile. 
Considering the carvone content in personal care products and the daily exposure resulting from the 
use of cosmetics, the Scientific Committee estimated that the exposure to d-carvone would be an 
average of 0.014 mg/kg bw/d and 0.022 mg/kg bw/d at the 95
th percentile. For l-carvone, the exposure 
would be an average of 0.35 mg/kg bw/d (0.08 mg/kg bw/d from toothpaste + 0.27 mg/kg bw/d from 
mouthwash) and 0.71 mg/kg bw/d at the 95th percentile (average of 0.08 mg/kg bw/d from toothpaste 
+ 95
th percentile of 0.63 mg/kg bw/d from mouthwash). 
The Scientific Committee notes that to its knowledge, no relevant default value for the estimated daily 
exposure to the use of toothpaste or mouthwash is currently available for the children population. 
Thus, in order to take into account this population in the aggregated exposure calculation from all 
carvone sources, the exposure values calculated for toothpaste/mouthwash for adults were also applied 
to  children.  The  Scientific  Committee  acknowledges  the  uncertainty  resulting  from  such  an 
assumption but considered that, while children have a lower body weight, they probably also use a 
lower amount of toothpaste (or mouthwash if used by children at all) as compared to adults. 
Based on this approach, the oral exposure of the children and adult populations to d-carvone is 0.014 
mg/kg bw/d on average up to 0.022 mg/kg bw/d at the 95
th percentile (Table 7). For l-carvone, the 
estimated oral exposure is 0.35 mg/kg bw/d on average up to 0.71 mg/kg bw/d at the 95
th percentile 
(Table 8). 
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Table 7:   Total aggregated oral exposure to d-carvone from all sources (feed additive, pesticides uses, food flavourings, natural food occurrence and 
personal care products) in five population groups (min-max estimates expressed in mg/kg bw/day) 
  Toddlers  Children  Adolescents  Adults  The elderly 
  Mean  High level  Mean  High level  Mean  High level  Mean  High level  Mean  High level 
Natural food occurrence
(c)  <0.0001-0.031  <0.0001-0.18  <0.0001-0.13  <0.0001-0.43  <0.0001-0.1  <0.0001-0.3  <00001-0.07  <0.0001-0.21  <0.0001-0.03  <0.0001-0.06 
Food flavourings  0.08-0.17  0.16-0.41  0.05-0.17  0.12-0.28  0.04-0.09  0.08-0.20  0.04-0.15  0.12-0.50  0.05-0.13  0.12-0.27 
Pesticide use on seed potatoes  Negligible  negligible  negligible  negligible  negligible  negligible  negligible  negligible  negligible  negligible 
Feed additives  <0.0001  <0.0002  <0.0001  <0.0002  <0.0001  <0.0002  <0.0001  <0.0002  <0.00005  <0.0001 
Personal care products
(a)  0.014  0.022  0.014
   0.022  0.014
   0.022  0.014
   0.022  0.014
   0.022 
Total aggregate oral exposure 
ranges for d-carvone from all 
sources (natural food 
occurrence, flavourings, 
pesticides uses, feed and 
personal care products)
(b) 
0.09-0.22  0.19-0.51  0.07-0.21  0.14-0.59  0.05-0.16  0.10-0.40  0.07-0.16  0.16-0.52  0.07-0.15  0.15-0.30 
Anticipated exposure range of d-
carvone from pesticide intended 
uses (ware and starch potatoes)   0.007-0.03  0.03-0.07  0.007-0.02  0.02-0.04  0.004-0.01  0.01-0.03  0.003-0.01  0.009-0.03  0.003-0.009  0.009-0.02 
Total aggregate oral exposure 
ranges for d-carvone from all 
sources (natural food 
occurrence, flavourings, 
pesticides uses, pesticides 
intended uses, feed and personal 
care products)
(b) 
0.10-0.25  0.21-0.56  0.08-0.23  0.16-0.60  0.06-0.17  0.11-0.42  0.07-0.18  0.16-0.53  0.08-0.16  0.16-0.31 
 
(a): Assuming that daily exposure to personal care products (toothpaste) estimated for adult population would be the same for toddlers, children and adolescents population 
(b): The exposure ranges were calculated using individual data from each survey. Note: it is not scientifically valid to simply sum all the high percentile values for each individual carvone source 
to derive the total high level exposure (95
th percentile) to carvone from all sources. Individuals who are high level consumers in one category are unlikely to be high level consumers in the 
other categories (EFSA, 2011a). 
(c): The impact of inserting the unspecified natural food sources was shown to be negligible (see section 4.1.9) Safety assessment of carvone 
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Table 8:   Total aggregated oral exposure to l-carvone from all sources (spearmint oil as pesticide, food flavouring, natural food occurrence and personal 
care products) in five population groups (min-max estimates expressed in mg/kg bw/day) 
  Toddlers  Children  Adolescents  Adults  The elderly 
  Mean  High level  Mean  High level  Mean  High level  Mean  High level  Mean  High level 
Natural food occurrence
(c),(d)  0  0  <0.0001  0  <0.0001  0  <0.0003  0  0  0 
Food flavourings  0.07-0.21  0.16-0.55  0.07-0.22  0.20-0.52  0.02-0.25  0.07-0.67  0.05-0.30  0.21-1.15  0.05-0.24  0.21-0.60 
Spearmint oil used as pesticide  0.002-0.009  0.01-0.02  0.002-0.005  0.006-0.01  0.001-0.003  0.004-0.008  0.001-0.004  0.003-0.01  0.001-0.003  0.003-0.005 
Personal care products
(a)  0.35  0.71  0.35  0.71  0.35  0.71  0.35  0.71  0.35  0.71 
Total aggregate oral exposure 
ranges for l-carvone from all 
sources
(b) 
0.42-0.57  0.87-1.27  0.42-0.58  0.92-1.23  0.37-0.60  0.78-1.38  0.40-0.65  0.92-1.87  0.40-0.60  0.92-1.31 
 
(a):  Assuming that daily exposure to personal care products (toothpaste and mouthwash) estimated for adult population would be the same for toddlers, children and adolescents population 
(b):  The exposure ranges were calculated using individual data from each survey. Note: it is not scientifically valid to simply sum all the high percentile values for each individual carvone 
source to derive the total high level exposure (95
th percentile) to carvone from all sources. Individuals who are high level consumers in one category are unlikely to be high level consumers 
in the other categories (EFSA, 2011a). 
(c):  Values reported as 0 means either that there is no consumption of food containing l-carvone reported in surveys either there is less than 5% of consumers of foods containing l-carvone in 
surveys 
(d):  The impact of inserting the unspecified natural food sources was shown to be negligible (see section 4.1.9) Safety assessment of carvone 
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4.1.9.  Aggregated oral exposure to d- and l-carvone from all sources 
The aggregated oral exposure to d- and l-carvone has been estimated by the Scientific Committee  
taking into consideration all the individual sources of exposure to d- or l-carvone described before 
(natural food occurrence, food flavourings, current and intended pesticide uses (sprouting inhibitor), 
feed additive, veterinary and medicinal use, and personal care products) (see sections 4.1.1 to 4.1.8). 
The  Scientific  Committee  has  performed  six  exposure  scenarios  (see  Table  9)  to  differentiate 
estimated exposures to d or l-carvone due to current uses from exposure expected from intended 
pesticide uses, and to take into account the uncertainties arising from the unspecified form of carvone 
from  natural  food  occurrence  or  from  the  lack  of  detailed  information  in  the  food  consumption 
database concerning the type of species of tea or herbs used for the preparation of tea and herbal 
infusions. 
Table 9 summarises the aggregate exposure estimates to d- and l-carvone. 
Table 9:   Summary of aggregate oral exposure scenarios to d and l-carvone from their uses in five 
population groups (min-max estimates expressed in mg/kg bw/day) 
  Toddlers  Children  Adolescents  Adults  The elderly  
  (12-35 
months)  (3-9 years)  (10-17 
years) 
(18-64 
years)  (>65 years) 
Scenario 1  
d-carvone  from  current  uses  (natural  food 
occurrence,  flavourings,  pesticides,  feed 
additive, personal care products); oral route  
  Mean  
  High level 
 
 
 
 
0.09-0.22 
0.19-0.51 
 
 
 
 
0.07-0.21 
0.14-0.59 
 
 
 
 
0.05-0.16 
0.10-0.40 
 
 
 
 
0.07-0.16 
0.16-0.52 
 
 
 
 
0.07-0.15 
0.15-0.30 
Scenario 2 
d-carvone  from  current  uses  (natural  food 
occurrence,  flavourings,  pesticides,  feed 
additive,  personal  care  products)  +  intended 
uses from pesticides; oral route 
  Mean  
  High level 
 
 
 
 
 
0.10-0.25 
0.21-0.56 
 
 
 
 
 
0.08-0.23 
0.16-0.60 
 
 
 
 
 
0.06-0.17 
0.11-0.42 
 
 
 
 
 
0.07-0.18 
0.16-0.53 
 
 
 
 
 
0.08-0.16 
0.16-0.31 
Scenario 3 
d-carvone  from  current  uses  (natural  food 
occurrence,  flavourings,  pesticides,  feed 
additive, personal care products) + unspecified 
form  of  carvone  for  natural  occurrence 
considered as d-carvone; oral route  
  Mean  
  High level 
 
 
 
 
 
 
0.09-0.22 
0.19-0.51 
 
 
 
 
 
 
0.07-0.21 
0.14-0.59 
 
 
 
 
 
 
0.05-0.16 
0.10-0.40 
 
 
 
 
 
 
0.07-0.16 
0.16-0.52 
 
 
 
 
 
 
0.07-0.15 
0.15-0.30 
Scenario 4 
l-carvone  from  current  uses  (natural  food 
occurrence,  flavourings,  pesticides,  personal 
care products); oral route 
  Mean  
  High level 
 
 
 
 
0.42-0.57 
0.87-1.27 
 
 
 
 
0.42-0.58 
0.92-1.23 
 
 
 
 
0.37-0.60 
0.78-1.38 
 
 
 
 
0.40-0.65 
0.92-1.87 
 
 
 
 
0.40-0.60 
0.92-1.31 
Scenario 5 
l-carvone  from  current  uses  (natural  food 
occurrence,  flavourings,  pesticides,  personal 
care  products)  +  unspecified  form  of  carvone 
for natural occurrence considered as l-carvone; 
oral route  
  Mean  
  High level 
 
 
 
 
 
 
0.42-0.57 
0.87-1.27 
 
 
 
 
 
 
0.42-0.58 
0.92-1.23 
 
 
 
 
 
 
0.37-0.60 
0.78-1.38 
 
 
 
 
 
 
0.40-0.65 
0.92-1.87 
 
 
 
 
 
 
0.40-0.60 
0.92-1.31 
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  Toddlers  Children  Adolescents  Adults  The elderly  
  (12-35 
months)  (3-9 years)  (10-17 
years) 
(18-64 
years)  (>65 years) 
Scenario 6 
l-carvone  from  current  uses  (natural  food 
occurrence,  flavourings,  pesticides,  personal 
care  products)  +  unspecified  form  of  carvone 
for natural occurrence considered as l-carvone 
+ 100% of tea/herbal solid and liquid (ready-to-
drink)  infusions  considered  as  l-carvone;  oral 
route 
  Mean  
  High level 
 
 
 
 
 
 
 
 
0.42-0.60 
0.91-1.50 
 
 
 
 
 
 
 
 
0.42-0.62 
0.92-1.39 
 
 
 
 
 
 
 
 
0.39-0.61 
0.85-1.38 
 
 
 
 
 
 
 
 
0.44-0.68 
0.96-1.87 
 
 
 
 
 
 
 
 
0.41-0.60 
0.93-1.43 
High level: 95
th percentile 
Based on this approach: 
  The estimated aggregated exposure to d-carvone (scenario 1: all current food uses and oral 
route, Tables 7 and 9) in the young population (including toddlers, children and adolescents) 
range from 0.05 mg/kg bw/d up to 0.22 mg/kg bw/d in average and from 0.10 mg/kg bw/d up 
to 0.59 mg/kg bw/day in high consumers. For the adult population (including the elderly), the 
estimates range from 0.07 mg/kg bw/d up to 0.16 mg/kg bw/d in average and from 0.16 mg/kg 
bw/d  up to  0.52  mg/kg  bw/day  in  high  consumers.  The  main  sources  contributing  to  the 
aggregated exposure are, depending on the population groups considered, on average and by 
decreasing order (Table 10): flavourings substances (from 34% up to 93%), personal care 
products (from 7% up to 28%) and natural food occurrence (from 14% up to 59%). Feed 
additives sources contribute less than 0.1% in all population groups and the contribution of the 
use of carvone as a pesticide on seed potatoes is negligible.  
  The estimated aggregated exposure to l-carvone (scenario 4: all current food uses and oral 
route, Tables 8 and 9) in the young population (including toddlers, children and adolescents) 
range from 0.37 mg/kg bw/d up to 0.60 mg/kg bw/d in average and from 0.78 mg/kg bw/d up 
to 1.38 mg/kg bw/day in high consumers. For the adult population (including the elderly), the 
estimates range from 0.40 mg/kg bw/d up to 0.65 mg/kg bw/d in average and from 0.92 mg/kg 
bw/d  up to  1.87  mg/kg  bw/day  in  high  consumers.  The  main  sources  contributing  to  the 
aggregated exposure are, depending on the population groups considered, on average and by 
decreasing order (Table 11): personal care products (from 54% up to 93%) and flavourings 
substances (from 6% up to 46%). Spearmint oil used as pesticide and natural occurrence of 
carvone in food contributes less than 2% and 0.05% respectively in all population groups. 
In  relation  to  the  anticipated  exposure  to  d-carvone  from  the  intended  pesticide  use  (sprouting 
inhibitor)  on  ware  and  starch  potatoes,  the  Scientific  Committee  performed  an  exposure  scenario 
(Scenario 2 in Tables 7 and 9), adding this additional use to the existing current food uses of d-carvone 
estimated in Scenario 1 (oral exposure from feed additive, pesticides uses, flavourings, natural food 
occurrence and personal care products). Depending on the population group and country considered, 
the resulting contribution from this anticipated use to the aggregate exposure estimates to d-carvone 
would range on average from 3% up to 21% (Table 10), depending on the quantity of potato-based 
products consumed in the country considered. Still, this new source of exposure to d-carvone would 
not result in the overall exposure to d-carvone exceeding the ADI.  
For several food sources, the configuration of the naturally occurring carvone enantiomer (d- or l-) has 
not  been  specified  (Table  3).  The  Scientific  Committee  took  this  uncertainty  into  account  by 
calculating exposure estimates (Table 9) based on the assumption that the unspecified enantiomers 
could be either l-carvone (scenario 3) or d-carvone (scenario 5). The resulting additional exposure to l-
or d-carvone, as compared to the estimated exposure to l- or d-carvone described above would be, for Safety assessment of carvone 
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all populations groups, up to 0.0005 mg/kg bw/d in average and up to 0.0013 mg/kg bw/day in high 
consumers. The Scientific Committee considered therefore the impact of the uncertainty resulting 
from the unspecified configuration of carvone naturally occurring in food on the estimated exposure to 
d or l-carvone as negligible. 
In relation to the uncertainty resulting from the lack of detailed information regarding the types of tea 
and  herbal  infusion  reported  in  the  EFSA  food  consumption  database,  the  Scientific  Committee 
performed a conservative exposure scenario (scenario 6 in Table 9), assuming that all tea and herbal 
infusions consumed in the database would be prepared from Mentha spicata containing l-carvone. The 
resulting  additional  exposure  to  l-carvone  as  compared  to  the  estimated  exposure  of  l-carvone 
described above (Scenario 4) would lead to estimates in average of up to 0.03 mg/kg bw/d in adult 
population and up to 0.045 mg/kg bw/d in young population, and of up to 0.13 mg/kg bw/d in high 
consumers adult population and of up to 0.22 mg/kg bw/d in high consumers young population. Based 
on the above, and considering that the adult high consumers exposure to l-carvone is not modified 
with  scenario  6,  the  Scientific  Committee  decided  to  base  the  aggregate  exposure  calculation  on 
scenario 4. 
Table 10:   Total  average  contribution  of  d-carvone  from  all  sources  to  the  aggregate  exposure 
estimates presented in Scenario 1 and from the contribution of intended pesticide uses in scenario 2 
(Table 9) in five population groups (min-max in %) 
   Toddlers  Children  Adolescents  Adults  The elderly 
   Mean  Mean  Mean  Mean  Mean 
Natural food occurrence
(a)  0.0-14.2  0.0-59.1  0-57.5  0.0-53.5  0.0-28.9 
Flavouring substances  79.3-92.6  34.3-90.4  33.9-86.9  35.8-91.4  56.5-90.0 
Pesticide use on seed potatoes  negligible  negligible  negligible  Negligible  negligible 
Feed additives  0.01-0.05  0.01-0.06  0.02-0.06  0.01-0.05  0.02-0.04 
Personal care products  6.5-15.2  6.6-19.9  8.5-27.6  8.6-21.5  9.4-19.7 
           
Intended pesticide use on ware  and starch 
products (from Scenario 2, Table 9):   3.6-20.5  4.6-20.1  4.0-15.5  2.9-9.9  3.5-7.7 
 
(a):  Values reported as 0 means either that there is no consumption of food containing d-carvone  reported in surveys or that 
there are fewer than 5% of consumers of foods containing d-carvone in surveys 
Table 11:   Total  average  contribution  of  l-carvone  from  all  sources  (spearmint  oil  as  pesticide, 
flavourings, natural food occurrence) and personal care products) to the aggregate exposure estimates 
presented in scenario 4 (Table 9) in five population groups (min-max in %) 
   Toddlers  Children  Adolescents  Adults  The elderly 
   Mean  Mean  Mean  Mean  Mean 
Natural food occurrence
(a)  0  0-0.02  0-0.03  0-0.05  0 
Flavouring substances   16.03-
36.9  15.8-38.5  6.1-41.8  11.7-45.6  13.2-40.8 
Spearmint oil used as pesticide   0.5-1.9  0.4-1.1  0.2-0.8  0.2-0.6  0.2-0.5 
Personal care products   61.7-83.2  60.5-83.3  57.9-93.4  53.8-87.9  58.7-86.4 
 
(a):  Values reported as 0 means either that there is no consumption of food containing l-carvone  reported in surveys or that 
there are fewer than 5% of consumers of foods containing l-carvone in surveys Safety assessment of carvone 
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4.2.  Hazard identification and characterisation 
4.2.1.  Toxicokinetics of carvone 
4.2.1.1.  General features of the metabolism of terpenes 
Monoterpenes such as carvone, citral, limonene, terpineol, or cineol are significantly present in food; 
their occurrence ranges from micrograms to even grams per kilogram of food. A typical example is 
their presence in spices to which they impart in many cases distinct aromas. For chiral terpenes, often 
only one of the enantiomers is present in foods, and their metabolism may be stereoselective.  
Terpenes are well absorbed from the gastrointestinal tract, in conjunction with fat which acts as a 
carrier. Their metabolism initiates either as a hydroxylation or an epoxidation step catalysed often by 
microsomal monooxidases such as cytochrome P-450 (CYP). Phase I metabolites (diols or carboxylic 
acids) are conjugated by phase II enzymes into. highly water soluble conjugates via sulfotransferases 
(sulfates),  UDP-glucuronosyltranferases  (glucuronides)  or  glutathione-S-transferases  (mercapturic 
acids),  prior  to  their  excretion  in  the  urine  (Engel,  2001).  For  monoterpenes,  entero-hepatic 
recirculation  of  glucuronide  conjugates  has  been  described  in  the  rat  but  has  not  been  shown  in 
humans. For example, toxicokinetics of menthol in the rat involves formation of the glucuronide, 
which  is  excreted  in  the  bile,  followed  by  cleavage  and  reabsorption  in  the  gut,  as  well  as 
hydroxylation into carboxylic acid derivatives which are excreted in the urine. The molecular weight 
of  menthol (156  g/mol) brings its  glucuronide  (331  g/mol)  within  the range for  extensive  biliary 
excretion  and  enterohepatic  recirculation  for  the  rat  (around  325  g/mol);  this  holds  also  true  for 
carvone  (150  g/mol)  (Yamaguchi  et  al.,  1994).  In  contrast,  data  for  toxicokinetics  of  menthol  in 
humans indicate that no enterohepatic recirculation occurs for menthol glucuronide since it is excreted 
readily in the urine (Hiki et al., 2011).  
4.2.1.2.  Metabolism and toxicokinetics of carvone 
(a) Available data from the literature 
In vivo investigations 
In vivo toxicokinetics data on d-or l- carvone in test species (rat, mice, rabbit, dog) have not been 
reported in the literature. Hence, basic toxicokinetic parameters for d- and l-carvone are not available 
for any routes of exposure (ECHA, 2013). In humans, d-carvone pharmacokinetics was investigated in 
15  male  volunteers  who,  after  a  10  h  fast,  took  5  capsules  of  an  immediate  release  formulation 
containing 20 mg caraway oil. Carvone concentrations in plasma were determined by GC/MS, with a 
limit of quantification of 0.5 ng/ml for carvone. Pharmacokinetic parameters were determined i.e. 
area-under the plasma-concentration curve (AUC) of 28.9± 20.0 ng.ml.h
-1, plasma peak concentration 
(Cmax) of 14.8±10.4 ng/ml with a time to reach Cmax (Tmax) of 1.3 hours and a half life of 2.4 
hours. Inter-individual differences determined as the coefficients of variation in AUC, Cmax and t1/2 
were 69%,74% and 50% respectively (Mascher et al., 2001). 
In vivo metabolism of d- and l-carvone has been investigated by Engel (2001) in six human volunteers 
(three males, three females) after oral dosing (1 mg/kg bw), with collection of urine samples 24 h 
before and after the ingestion of each enantiomer separately. Chemical structures of the metabolites 
were elucidated using mass spectral analysis in combination with metabolite syntheses and NMR 
analysis.  For  this,  the  urinary  samples  were  treated  with  sulphatase  and  glucuronidase,  assuming 
conjugation of phase I metabolites. However, no quantitative data on excretion of conjugated forms of 
the metabolites were reported. The study identified three side-chain oxidation products as the main 
primary  unconjugated  metabolites  of  d-  and  l-carvone:  dihydrocarvonic  acid,  carvonic  acid,  and 
uroterpenolone,  with  10-hydroxycarvone  as  the  proposed  intermediate  metabolic  step.  However, 
unlike other species, the presence of 10-hydroxycarvone was not detected in humans and Engel (2001) 
suggested this was due to more efficient oxidation of 10-hydroxycarvone leading to carvonic acid. Safety assessment of carvone 
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According to Engel (2001), there were no differences in the metabolism of d- and l-carvone. However, 
the  results  presented  only  refer  to  “after  carvone  ingestion”,  although  apparently  both  carvone 
enantiomers  were  ingested  by  the  volunteers  in  independent  trials.  According  to  the  author,  all 
metabolites were identical after the application of either d- or l-carvone. However, the configurations 
of metabolites were not identified and the chromatographic analyses were only performed on a non-
chiral stationary phase. This experimental set-up does not allow differentiation of the stereospecific 
metabolism of d- and l-carvone.  
Engel (2001) also speculated on the existence of an alternative pathway that could have led to the 
direct formation of dihydrocarvonic acid through conversion of carvone to epoxide, rearrangement to 
saturated  aldehyde,  and  followed by  oxidation to  dihydrocarvolic  acid. The study  detected  minor 
metabolites  in  the  form  of  reduction  products  of  carvone,  namely,  the  alcohols  carveol  and 
dihydrocarveol (Figure 1), and thus confirmed findings of in vitro investigations (e.g. Jaeger, 2000; 
Shimada  et  al.,  2002)  that  the  reductive  metabolic  transformation  of  carvone  (to  carveol  and 
dihydrocarveol) is a minor side pathway in humans. In a further study, Engel (2002) investigated the 
formation of dihydrocarvonic acid, carvonic acid and uroterpenolone after human ingestion of 9,9-
dideutero- and 9-[13]C-carvone. The study found that carvonic acid was formed by oxidation at the 
methyl carbon of the isopropenyl group of carvone, whereas dihydrocarvonic acid was formed by 
oxidation at the methylene position, most probably via carvone epoxide. Uroterpenolone was found to 
be exclusively formed by oxidation at the methylene carbon of the isopropenyl group of carvone, and 
thus, most probably by hydrolysis of carvone epoxide. 
In vitro investigations 
A study by Jaeger (2000) investigated in vitro metabolism of l- and d-carvone by rat and human liver 
microsomes. The study observed the biotransformation to be stereoselective as (4R,6S)-carveol was 
NADPH-dependently formed from (4R)-carvone (l-carvone), and (4S,6S)-carveol was produced from 
(4S)-carvone  (d-carvone).  A  significantly  lower  apparent  Km  (Michaelis-Menten  Constant)  was 
observed for the formation of (4R,6S)-carveol compared to (4S,6S)-carveol both in rat and human 
liver  microsomes  with  the  Vmax  for  human  liver  microsomes  almost  twice  that  for  rat  liver 
microsomes.  Incubation  of  the  carveol  enantiomers  with  rat  and  human  liver  microsomes  in  the 
presence  of  uridine  S'-diphosphoglucuronic  acid  (UDPGA)  showed  that  only  l-carveol  was 
glucuronidated. The Vmax for glucuronide formation was more than 4-fold higher for the rat liver 
compared with human liver preparations with equivalent Km values. Shimada et al. (2002) studied 
species differences in the metabolism of d- and l- limonene and metabolites (carveols and carvones) 
by CYPs in liver microsomes. Metabolism of (4S)-carvone (d-carvone) to (4S,6S)-carveol by male rat 
liver microsomes was around x20 higher than by human liver microsomes whereas metabolism by 
female rat liver microsomes  was 2.5 lower than by human liver microsomes. The study also used 
recombinant (T. ni) cells expressing human and rat CYPs along with co-expression of NADPH-P450 
reductases. The human CYPs with the highest activities for conversion of (4S)-carvone (d-carvone) to 
(4S,6S)-carveol were found to be CYP2C9 and CYP2C19, followed by CYPs 3A4, 2E1, 2C18, and 
2C8. In rats, CYP2C11 and CYP2B1 catalysed conversion of (4S)-carvone (d-carvone) to (4S,6S)-
carveol at high rates, whereas female specific CYP2C12 had only very low activity. The study also 
showed that d-carveol could be converted back to d-carvone in some species, but not in humans or 
rats.  Although  the  study  is  based  on  in  vitro  investigations,  it  does  highlight  important  species 
differences in the rate of metabolic conversion of carvone to carveol between human and rat, and 
points  out  to  a  possible  very  low  rate  of  metabolism  of  carvone  in  female  rat.  The  Scientific 
Committee noted that only glucuronidation of d- and l-carveol has been investigated; glucuronidation 
of  d-  and  l-carvone  and  their  other  metabolites  (carvonic  acid,  dihydrocarvonic  acid  and 
uroterpenolone, dihydrocarveol) has not been studied. Safety assessment of carvone 
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Figure 1:   Proposed phase I routes of metabolic transformation for carvone in humans (adapted from 
Engel, 2001). 
There is evidence that carvone and its metabolites induce detoxification enzymes such as glutathione 
S-transferases in several tissues of mice, with d-carvone and the unsaturated ketone groups being more 
potent than l-carvone in all tested tissues (liver, kidney). This induction of detoxification enzymes by 
carvone and its metabolites has been correlated in test species in vivo with potential chemopreventive 
properties (Zheng et al., 1992; De Carvalho and da Fonseca, 2006). An example of such a correlation 
between enzyme induction and chemopreventive properties has been demonstrated in female A/J mice 
where d-carvone inhibited N nitrosodiethylamine- induced carcinogenesis through the reduction of 
forestomach  tumour  formation  (around  60%)  and  pulmonary  adenoma  (35%)  (Wattenberg  et  al., 
1989). In a 16 week rat study, antioxidant activities were induced by d-carvone (10 mg/kg) in the liver, 
proximal colon and distal colon (as measured by superoxide dismutase and glutathione peroxidase, 
glutathione  reductase,  glutathione-S-transferase  and  UDP-glucuronyltransferases).  This  enzyme 
induction was then associated with 78% reduction of the incidence of colonic polyps and aberrant 
crypt foci in 1,2-dimethylhydrazine (DMH)-induced experimental colon carcinogenesis. The authors 
also noted that the bioactivation of DMH to its carcinogenic metabolite was inhibited by carvone 
treatment (through inhibition of CYP2E1) (Vinothkumar et al., 2013). 
Conclusions on metabolism part: 
  The findings of the in vitro and in vivo studies indicate that carvone is metabolised differently 
in humans and rats; 
  The main metabolites of carvone in humans in vivo are carvonic acid, dihydrocarvonic acid Safety assessment of carvone 
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and uroterpenolone, with carveol and dihydrocarveol as minor products. However, this study 
did not assess the stereospecificity of the metabolism of carvone in humans; 
  There  are  in  vitro  indications  for  stereoselective  reduction  of  carvone  to  carveol  and 
stereospecific conjugation (only l-carveol is glucuronidated and with a four-fold higher rate in 
the  rat  compared  with  humans).  Glucuronidation  of  d-  and  l-carvone  and  their  other 
metabolites (carvonic acid, dihydrocarvonic acid and uroterpenolone, dihydrocarveol) has not 
been studied; 
  In rat, carveol is likely to be the main metabolite. The evidence from in vitro studies suggests 
that metabolic conversion of carvone to carveol in female rat liver is likely to be very slow 
compared to male rat. 
(b) In-silico predictions of mammalian metabolism of carvone 
Because of the very limited availability of experimental data, different in silico methods, including 
(Q)SAR models, expert systems, and read-across, were used to predict 1) the metabolic fate of carvone 
in mammals and 2) the metabolic half-life, intestinal uptake, bioaccumulation, and/or toxicity of the 
predicted metabolites. The aim was to investigate whether there are other intermediates or metabolites 
of carvone in rats and human that are not reported in the literature.  
Predicted Metabolism in Rat 
The metabolic predictor Metaprint 2D
13 was used to predict the most likely sites and the resulting 
metabolites of carvone. The Metaprint 2D plugin to Bioclipse 2.6
14 also allows the option to examine 
the  metabolic  sit es  of  a  molecule  using  dog,  rat   or  human  metabolic  pathway  databases. 
Stereoselective  metabolism  cannot  be  addressed  with  this  predictor.  The  results  showed  that 
metabolism of carvone is likely to differ in humans (largely site 1) from that in rats (site 2 and 3) with 
a probability between 0.66 and 1.0 (Figure 2). This is consistent with the available data as described 
above. 
 
Figure 2:   Metabolic sites of carvone in rats and humans predicted by Metaprint 2D 
 
                                                       
13 www-metaprint2d.ch.cam.ac.uk 
14 www.bioclipse.net/ Safety assessment of carvone 
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The main metabolites predicted by Metaprint 2D in humans are listed below: 
 
. 
 
 
The  simulator  predicted  both  uroterpenolone  (metabolite  1)  and  the  minor  metabolite  carveol 
(metabolite 3) but did not predict the other two main metabolites in humans  - carvonic acid and 
dihydrocarvonic acid. A second in silico system SMARTcyp
15 was used to predict the sites in carvone 
that are most liable to metabolism by CYPs. This system has been shown to be applicable to 
metabolism by CYPs 1A2, 2A6, 2B6, 2C8, 2C19, 2E1, and 3A4. Other specific models for CYP2C9 
and CYP2D6 are al so included within version 2.1 of the programme. SMARTCyp predicted the 
following most probable metabolites from likely metabolic sites in a ranked order. 
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In  the  ranked  order  of  most  probable  metabolites,  SMARTCyp  predicted  intermediate  10-
hydroxycarvone,  but  did  not  predict  carvonic  acid  or  dihydrocarvonic  acid.  It  appears  that 
SMARTCyp  and  other  simulators  are  more  inclined  towards  predicting  epoxides  and  other 
intermediates but not the final oxidation/hydroxylation steps to respective alcohols and  carboxylic 
acids.  When used together, these  in  silico  metabolic  simulators  provide  an insight  to  the  various 
intermediates and metabolites that might be formed within metabolic pathways for carvone.  
In conclusion, the in silico tools support the site differences for carvone metabolism between rat and 
humans, and predicted the potential intermediate compounds produced during metabolism.  
Intestinal Absorption and metabolic half-life 
The profilers contained within the OECD Toolbox allow the estimation of human intestinal absorption 
(HIA) and the metabolic half lives for carvone and its metabolites:  
  The profiler in the Toolbox for Lipinski Rule of Five (see Glossary) classified carvone and the 
predicted carvone metabolites as readily absorbed within the gastrointestinal (GI) system.  
  The metabolic half-lives for phase I carvone metabolites were predicted to range between 0.03 
and 0.5 day (compared with 0.5 day for carvone). The metabolic half-lives for the phase II 
metabolites were predicted to be either fast (0.1-1 days), which is equivalent to carvone, or 
very fast (<0.1 day). These estimates are however derived from profilers based on fish data 
                                                       
15 www.farma.ku.dk/smartcyp/about.php 
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from EPISUITE and therefore may not be directly relevant to carvone metabolism in humans.  
  The  estimates  for  Human  Intestinal  Absorption  (HIA)  of  the  metabolites  derived  from 
MultiCase  module  within  the  OECD  Toolbox  were  between  83  and  90%,  which  is  also 
comparable to the estimated value for carvone (93%).  
In conclusion, the in silico assessments predicted that carvone is metabolised at different sites of the 
molecule  in  rats  and  humans,  providing  further  supporting  evidence  to  the  in  vivo  and  in  vitro 
metabolism data. In addition, the in silico assessments also predicted that carvone and its metabolites 
are readily absorbed by the GI tract and have similar metabolic half-lives.  
4.2.1.3.  Contribution to carvone exposure through metabolism of limonene 
The  metabolism  of  limonene  was  considered  to  assess  whether  limonene  exposure  potentially 
contributes to carvone internal dose. In vivo metabolism studies in rat, guinea pig, hamster, rabbit, dog 
and humans have quantified the respective metabolites of d-limonene in urine and identified two major 
metabolic routes: 
- Oxidation of methyl groups to hydroxy groups and further oxidation to carboxylic acid derivatives 
(perillic acid),  
- hydroxylation at C-6 (p-mentha-1,8-dien-6-ol, carveol) and then further oxidation at C-8, 9 double 
bonds (p-menth-1-ene-6,8,9-triol) and glucuronidation.  
Interspecies differences were observed through measurement of excretion of urinary metabolites as a 
percentage of the dose. Perillic acid and its metabolites constituted the major metabolic route in the rat 
(85%), rabbit, hamster and guinea pig (50-65%), 20-40% in dog and humans whereas excretion of p-
menth-1-ene-6,8,9-triol d-limonene and its glucuronide represented 60-70% in dog and humans , 6% 
in the rat and 30-45% in the rabbit, hamster and guinea pig. Since no carvone is formed during 
limonene metabolism, it can be concluded that limonene does not contribute to carvone internal dose 
(Kodama et al., 1976).  
Conclusions on toxicokinetics of carvone 
d-Carvone toxicokinetics in humans features rapid elimination with a half life of 2.4 hours, no data are 
available for l-carvone. No toxicokinetic data on carvone in animals are available. The evidence from 
in vivo, in vitro and in silico assessments has shown that carvone metabolism is likely to be different 
in humans and rats – with further possible differences between metabolism in male and female rats. It 
is also evident that when compared with carvone itself, the metabolites are not likely to be different in 
terms of GI uptake or half-life in the body. Toxicokinetic data on other monoterpenes in the rat such as 
menthol  suggest  that  metabolism  involves  conjugation  to  a  glucuronide  for  which  enterohepatic 
recirculation occurs in the rat but not in humans. Considering the molecular weight of glucuronidated 
carvone metabolites, they may undergo enterohepatic recirculation in rats but not in humans, making 
the  rat  more  sensitive  than  humans  for  these  compounds.  Further  investigation  of  toxicokinetics 
(including basic parameters such as absorption (bioavailability), distribution (volume of distribution), 
metabolism and excretion (potential enterohepatic recirculation half life, clearance…) is required for 
both enantiomers.  
4.2.2.  Toxicity of carvone 
For  the  present  assessment,  the  Scientific  Committee  considered  the  data  on  the  metabolism, 
toxicokinetics and toxicity for d- and l-carvone retrieved from the extensive literature searches, as well 
as  the  key  studies  that  have  driven  previous  risk  assessments  performed  by  international  bodies 
(JECFA, US-EPA, ECHA, NTP). No additional references on sub-acute and sub-chronic toxicity of 
carvone in test species or humans were identified from the extensive litearture searches. No study of Safety assessment of carvone 
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the  sub-acute an sub-chronic  toxicity of l-carvone  could be  identified at any stage of the review 
process. 
4.2.2.1.  Acute Toxicity 
The oral LD50 of carvone (d/l ratio unspecified) in Wistar Crl: WI (Han) rats has been reported as 
>2000  mg/kg  bw  when  assessed  using  the  up  and  down  procedure  (OECD  425)  (Lütkenhaus, 
2013a,b).  
For d-carvone, the oral LD50 was 1,640 mg/kg bw in rats (unspecified strain) and 766 mg/kg bw for 
guinea pigs (Jenner et al., 1964).  
Preliminary work for the NTP 90-day rat study included the determination of oral LD50 values in 
Fischer rats: 
LD50 males: 3430 mg/kg bw    95% confidence interval: 2442-4816 mg/kg bw  
LD50 females: 2263 mg/kg bw    95% confidence interval: 1822-2810 mg/kg bw  
LD50 combined: 2786 mg/kg bw   95% confidence interval: 2254-3443 mg/kg bw 
For l-carvone, the oral LD50 in rats was found to be around 5400 mg/kg bw (Quest International, 1986, 
US-EPA, 2009).  
The intravenous LD50 value for d-carvone in mice was 1,500 mg/kg (Lichtenstein et al., 1974). Stoner 
et al. (1973) reported that no adverse effects were observed in mice given six intraperitoneal injections 
of 250 mg/kg bw d-carvone over a 2-week period. 
The LD50 by the dermal route in rat is reported to be >4000 mg/kg bw for carvone with no specified 
enantiomer ratio (Allen, 1995).  
For the intraperitoneal route, LD50 values for d- and l-carvone in male Swiss mice were below 500 
mg/kg bw, namely 484.2 (358.9–653.2) mg/kg bw for d-carvone, and 426.6 (389.0– 478.6) mg/kg bw 
for l-carvone. Both enantiomers caused depressant effects on the central nervous system, including a 
decrease in touch and ambulation response, an increase in sedation, as well as antinociceptive effects. 
Pentobarbital sleeping time was also measured and l-carvone was more effective than d-carvone at 100 
mg/kg, but was less potent at 200 mg/kg compared to the d-carvone enantiomer (De Sousa et al., 
2007).  
The LC50 by the inhalation route was found to be >5.66 g/m
3 for carvone with a d/l enantiomer ratio of 
approximately 4/1 (Arts, 1996).  
Clinical signs after acute exposure were different depending on the route of exposure. After acute oral 
administration, these  included  hunched  posture  and  lethargy  and  occasional  body  tremor  with  no 
abnormalities at necropsy. After acute dermal exposure no systemic or skin effects were observed 
whereas after inhalation of carvone, respiratory effects were noted as well as alopecia and impairment 
of body weight gain (ECHA, 2013).  
4.2.2.2.  Sub-acute and sub-chronic toxicity studies 
As indicated in section 4.2.2, no study of the sub-acute an sub-chronic toxicity of l-carvone could be 
identified at any stage of the review process. The studies described in the following section are all 
investigating the effects of d-carvone. Safety assessment of carvone 
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(a)  Studies of the National Toxicology Program 
14-day study in rats (NTP, 1982) 
A preliminary study was conducted in which groups of 5 Fischer 344 rats of both sexes received d-
carvone by gavage at doses of 0, 150, 328, 723, 1 590 or 3 500 mg/kg bw/day 5 days per week (they 
received 12 doses over 16 days) receiving 4 consecutive doses before termination.  
All rats at the highest two doses died during the first week of treatment and clinical signs reported 
included  tonic  convulsions,  prostration,  gasping,  salivation,  ataxia,  bradypnea,  impaired  righting 
reflex, hypoactivity, ptosis and decreased grasping reflex. No specific compound-related macroscopic 
or  microscopic  findings  were seen  in the  animals  which  died. There  were statistically  significant 
differences  in  mean  liver,  heart,  thymus  and  kidney  weights  among  the  surviving  treated  groups 
compared with controls but there is no other information available on these results. 
90-day study in rats (NTP, 1982) 
Groups of 10 Fischer 344 rats per sex were administered d-carvone by gavage at 0, 93, 187, 375, 750 
and 1500 mg/kg bw per day. Rats were housed 5 per cage and were observed daily and in more detail 
once weekly. Body weight was recorded at the start and end of treatment and weekly in between. Male 
reproductive function was tested in 5 rats from the groups receiving 0, 93 and 375 mg/kg bw/day at 
weeks 2, 4, 6 and 8 of the study (20 additional animals were included in each of these groups for this 
purpose. Semen was collected and assessed for sperm concentration, motility and morphology. The 
same examination was conducted on all survivors at scheduled necropsy. Complete necropsy was 
performed on all animals with a full macroscopic examination and weights of brain, lungs, heart, 
thymus,  liver,  right  testis  and  right  kidney  recorded.  A  full  range  of  tissues  was  preserved  and 
processed to slides for histological examination for all controls, all animals which died during the 
study  and  all  animals  from  the  group  given  375 mg/kg  bw/day.  The  study  did  not  include  any 
examination of haematology, clinical chemistry or urine parameters. 
Most animals from the two highest dose groups (750 and 1500 mg/kg bw/day) died during the study; 
those from the highest dose group were dead within 3 days of study start. Clinical signs recorded for 
these animals included hypoactivity, coat unkempt, piloerection, dehydration, excessive salivation, 
wet yellow stained anogenital region, impaired righting reflex, decreased grasping reflex, decreased 
limb tone, hypothermia, ataxia and prostration.  
Body weight was reduced compared with controls by approximately 9% for males from the groups 
given 187 and 375 mg/kg bw/day. Female body weights were not significantly affected. Due to the 
male body weight differences relative organ weights may be a slightly better index of any effect for 
males.  
Mean relative kidney weight for both sexes was significantly increased compared with controls at 
375 mg/kg bw/day and for males only at 187 mg/kg bw/day; means for the females at 187 mg/kg 
bw/day and both sexes at 93 mg/kg bw/day were slightly higher than control but the difference was 
not statistically significant. Kidney degeneration was reported for 27/30 males from the 1 500 mg/kg 
bw/day group and 7 from the group given 750 mg/kg bw/day. For the 375 mg/kg bw/day group males, 
one animal had renal dilatation and three has tubular protein casts in the kidney but otherwise no 
degenerative changes. 
The  relative  liver  weight  of  the  surviving  dose  groups  (93,  187  and  375 mg/kg  bw/day)  was 
statistically  significantly  increased  compared  with  controls  (t-test,  P<  0.05).  This  difference  was 
present in both sexes, was dose-related and there was no dose without effect. There was a report of 
cytoplasmic vacuolation in the liver of 3/10 male rats given 375 mg/kg bw/day and some similar Safety assessment of carvone 
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changes in those dying from the 1 500 mg/kg bw/day group but not from those given 750 mg/kg 
bw/day. 
The specific tests for sperm concentration, motility and morphology were revised after the study was 
reported and showed some differences between treated and control groups. For males given 375 mg/kg 
bw/day  there  was  depressed  sperm  motility  and  a  mild  decrease  in  sperm  concentration,  in  the 
assessments made at the end of the study but not on any other occasion. Similar changes were seen in 
the only male surviving to the end of the study from the 750 mg/kg bw/day group, however in all the 
males from that group there was testicular degeneration and relative aspermia. No effects were seen on 
testes or sperm parameters or any aspect of reproductive function at lower doses. 
In the stomach of 3/10 males and in 2/10 females from the 750 mg/kg bw/day group, gastric mucosal 
ulceration  involving  both  glandular  and  non-glandular  regions  was  recorded  at  necropsy  and 
confirmed by microscopic examination.  
16-day study in mice (NTP, 1990) 
Groups of five B6C3F1 mice were given d-carvone by gavage at doses of 0, 150, 328, 723, 1590 or 
3500 mg/kg bw/day for 5 days per week (they received 12 doses over 16 days). Mice were housed 
5/cage and were observed daily, weighed on days 1, 7 and 14 and at termination. A necropsy was 
performed  on  all  animals and  brain,  heart,  liver,  right  kidney,  lungs  +  bronchi  and  thymus  were 
weighed;  a  full  range  of  tissues  was  preserved  for  histological  examination.  Histopathology  was 
performed on the animals given the highest dose. 
All mice receiving 1590 or 3500 mg/kg bw/day died on day 2 or 3; clinical observation in these 
animals included ataxia, impaired grasping reflex, ocular discharge, corneal opacity, body tremors, 
prostration, gasping, clonic or tonic convulsions and impaired righting reflex. 
Relative  liver  weights  were  increased  for  surviving  treated  male  mice  at  all  doses  (150,  328, 
723 mg/kg bw/day), although not in a dose-related pattern; thymus weights were decreased for treated 
females but again the pattern was not dose-related. There was no treatment-related histological change 
reported but the NTP report does not detail which tissues from which group were actually examined 
(i.e. the study plan indicated that the highest dose would be examined). 
90-day study
 in mice (NTP, 1990) 
Groups of ten B6C3F1 mice of each sex were given d-carvone by gavage at doses of 0, 93, 375 or 
1 500 mg/kg  bw/day  for  5  days  per  week  for  13  weeks;  groups  of  10  mice  of  each  sex  were 
administered 187 or 750 mg/kg bw/day on the same schedule. Mice were housed 5/cage and were 
observed daily, weighed on days 1, 7 and 14 and at termination. A necropsy was performed on all 
animals during which organs were weighed and a full range of tissues was preserved for histological 
examination. Histopathology was performed on the controls, animals killed at 2, 4, 6 and 8 weeks and 
all animals which died during the study plus those given 750 mg/kg bw/day. 
All male mice and 9/10 females receiving 1 500 mg/kg bw/day died before the end of the study, 
mostly  in  the  first  week  of  treatment.  Clinical  signs  reported  were  hypoactivity,  ataxia  and 
hypersensitivity to touch 
Mean liver weight was higher than that of controls for both sexes receiving 750 mg/kg bw/day, this 
was not associated with any histological change. Otherwise organ weights were similar in treated and 
control groups. Safety assessment of carvone 
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(b)  Studies  used  in  the  European  pesticide  active  substance  peer  review  process to  establish the 
Acceptable Daily Intake for d-carvone (conducted with a product with a minimum purity of 95% 
d-carvone) 
14-day range-finding study in rats (Schoenmakers, 1995) 
This study used groups of 5 Wistar Crl : (WI) BR rats per sex given daily doses of 0, 50, 200 and 
1000 mg d-carvone/kg bw/day by gavage for 14 days. Rats were monitored daily for condition and 
behaviour; body weight and food consumption were recorded weekly. At the end of the study blood 
samples were taken from the retro-orbital sinus and examined for RBC, Hb, HCT, MCV, MCHb, 
MCHC, Platelet count, Red cell distribution width, WBC, Differential WBC, PT and PTT. Serum 
separated from the same samples was examined for ALAT, ASAT, Bilirubin, creatinine, glucose, urea, 
total protein, albumin, ALP, Na, K, Cl, Ca and P. At the end of the study all rats were subject to a 
necropsy including gross examination and weighing of adrenals, heart, kidneys, spleen and testes. 
Samples of these together with stomach and any abnormal tissues were preserved for microscopic 
examination but no examination was performed. 
At  the  highest  dose  (1000 mg/kg  bw/day)  all  animals  were  killed  in  extremis  on  days  5-7,  after 
displaying  clinical  signs,  including  reduced  body  weight  and  food  consumption.  Macroscopic 
examination at necropsy showed evidence of gastric irritation (thickening of the limiting ridge and 
alterations in forestomach epithelium). These animals showed signs of lethargy, hunched posture, 
uncoordinated movements, piloerection, emaciation, abnormal posture, recumbency, quick breathing 
and diarrhoea from day 4 onwards.  
No haematology or clinical chemistry data were obtained for the highest (1000 mg/kg bw/day) dose 
group. Prothrombin time was significantly reduced in males at the 200 mg/kg bw/day dose, otherwise 
there was no indication of any treatment-related effects on haematology or clinical chemistry. 
Mean  relative  kidney  weight  and  heart  weight  of  males  was  significantly  increased  compared  to 
controls but there was no sign of a similar difference in females.  
90-day study in rats (Schoenmakers, 1996) 
Groups of 10 Wistar Crl : (WI) BR rats of each sex were administered d-carvone in corn oil vehicle by 
gavage at doses of 0, 5, 30, and 180 mg/kg bw/day, in accordance with GLP and OECD Guideline 408 
(1981). Rats were monitored daily for condition and behaviour; body weight and food consumption 
were recorded weekly. Ophthalmoscopy was carried out prior to treatment and at the end of the study 
on all rats. At the end of the study blood samples were taken from the retro-orbital sinus and examined 
for  RBC,  Hb,  HCT,  MCV,    MCHb,  MCHC,  Platelet  count,  Red  cell  distribution  width,  WBC, 
Differential WBC, PT and PTT. Serum separated from the same samples was examined for ALAT, 
ASAT, bilirubin, creatinine, glucose, urea, total protein, albumin, ALP, Na, K, Cl, Ca and P. 
At the end of the study all rats were subject to a necropsy including gross examination and weighing 
of adrenals, brain, heart, kidneys, liver, ovaries, prostate, spleen, testes and thymus. Samples of a full 
range of tissues were preserved for microscopic examination. Slides were prepared from all tissues of 
the  control  and  high  dose  groups  and  examined  microscopically.  Based  on  the  findings  of  this 
examination kidneys were examined from the remaining two treatment groups. 
There  were  no  clinical  observations  that  were  considered  to  be  related  to  treatment  and  no 
abnormalities observed in the ophthalmoscopic examination. Slightly reduced body weight gain of 
males at the highest dose (180 mg/kg bw/day) was matched by a reduced food intake.  Safety assessment of carvone 
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There  were  no  treatment-related  effects  on  the  haematological  results  apart  from  reduction  of 
prothrombin time (PT) of 180 mg/kg bw/day males (since a similar difference was present in the 
results of the 14-day study this may not be a chance finding) and a significant increase in partial 
thromboplastin time (PTT) for 180 mg/kg bw/day females.  
Clinical chemistry results are mostly similar for treated and control groups but high dose males had a 
significant reduction in ASAT and a reduction was also seen in females at the same dose but the 
difference  was  not  significant.  Apart  from  a  non-dose-related  reduction  (approx  10 %)  in  serum 
calcium in all treated female groups there were no treatment-related differences between the groups in 
the results of clinical chemistry analyses.  
Organ weights and weights expressed  relative to body weight were similar for treated and control 
groups  apart  from  those  for  liver  and  kidney.  The  relative  liver  weights  of  both  sexes  were 
significantly higher than those of controls at the highest dose and in females also at the intermediate 
dose. Mean relative kidney weights were significantly increased compared with controls for both sexes 
at the highest and intermediate dose. Although some statistically significant differences were seen 
between controls and treated animals in thymus and spleen weights these were confined to females 
and were not dose-related and are thus considered unlikely to be due to treatment.  
Microscopic examination revealed no histopathological changes related to treatment apart from those 
in the kidney which consisted of tubular necrosis, exclusively in male rats, and basophilic tubules in 
both sexes. These effects were subject to further investigation, as described below.   
Histopathological review (Woutersen and Bos-Kuijpers, 2003)  
A re-evaluation of the kidney slides from the 90-day study looked at the kidney slides from both sexes 
for all groups and concluded: 
“Re-evaluation of the kidney slides of rats of the 90-day oral (gavage toxicity study with carvone min. 
95 % resulted in the conclusion that the renal histopathological lesions observed in male animals of the 
mid and high-dose group were most probably related to the renal accumulation of  2u -globulin. This 
conclusion  was  confirmed  by  highly  positive  staining  of  the  treated  (high  dose  group  rats  with 
antibody against  2u -globulin.  
Based on these observations it is concluded that the renal histopathological changes observed in male 
rats treated with 30 or 180 mg/kg bw per day carvone min. 95 % are caused by accumulation of  2u -
globulin in the proximal tubular cells and hence are diagnosed as  2u -globulin nephropathy.” 
A further report reaching similar conclusions was issued by the conducting laboratory following this 
review of histopathology on the kidney slides from male rats (Schoenmakers, 2003). 
4.2.2.3.  Chronic toxicity and carcinogenicity of d-carvone (NTP, 1990) 
Groups of fifty B6C3F1 mice of each sex were given d-carvone by gavage at doses of 0, 375 or 
750 mg/kg bw/day for 5 days per week for 103 weeks. Mice were housed 5/cage and were observed 
daily.  Animals  were  weighed  weekly  up  to  13  weeks  and  then  approximately  monthly  for  the 
remainder of the study. Survival at two years was better for female treated groups than for controls 
(14/50; 29/50; 38/50 for control, low dose and high dose respectively) due to a high incidence of 
urogenital abscesses in controls. Survival of males was similar for all groups (37/50; 42/50; 36/50 for 
control low dose and high dose respectively). Body weight of treated animals was similar to that of 
controls  throughout  the  study.  The  only  non-neoplastic  lesions  which  were  considered  related  to 
treatment were atrophy of olfactory  epithelium and hyperplasia of  the  underlying  Bowman’s glands;  Safety assessment of carvone 
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these were considered most likely to be an artefact deriving from reflux of d-carvone following the 
gavage administration. There was no evidence of any treatment-related non-neoplastic changes in the 
liver or kidney. There was no evidence of carcinogenic activity of d-carvone.  
A chronic study in F344/N rats was mentioned in the introduction to the mouse study and described as 
being  terminated  at  13  months  without  any  examination  of  tissue  or  any  reporting  of  data. The 
termination was described as due to performance issues in the laboratory conducting the study. No 
further details are available. 
No chronic study was available for l-carvone.  
4.2.2.4.  Developmental and reproductive toxicity 
2-Generation reproduction study (Beekhuijzen, 2004) 
Groups of 25 male and 25 female Wistar Crl : (WI) BR rats were given 0, 3, 10 or 30 mg/kg/day of d-
carvone (95 %) in corn oil vehicle for 10 weeks prior to mating until termination. The study was 
conducted according to GLP and to OECD Guideline 416 (OECD, 2001). 
For the F1 generation the dose levels were revised to 0, 10, 30 and 90 mg/kg/day. All animals were 
checked  at  least  once  daily  for  clinical  signs  and  condition.  Body  weight  and  food  consumption 
measurements were recorded weekly. Females were mated individually and remained with the litters 
during weaning. Pups were not treated during the weaning period. On day 4 after birth all litters of 
more than 8 pups were culled  to approximately 4 males and 4  females. After weaning of the F1 
generation,  animals  were  selected  and  again  treated  for  10  weeks  prior  to  mating  and  up  to 
termination. F0 males were killed as soon as possible after successful mating while F1 males were only 
killed after successful delivery of the dams. Females from both generations were killed at day 21 post 
partum. All parental animals were subject to a necropsy and some tissues weighed (adrenals, brain, 
epididymides,  kidneys,  liver,  ovaries,  pituitary,  prostate,  seminal  vesicles,  spleen,  testes,  thyroid, 
uterus  with  oviducts  and  cervix)  also  a  range  of  tissues  (adrenals,  brain,  coagulating  glands, 
epididymides, identification marks, kidneys, liver, ovaries, pituitary, prostate, seminal vesicles, spleen, 
testes, thyroid, uterus with oviducts and cervix, vagina) preserved for histological examination. All 
pups not selected for mating were taken for necropsy at day 21 post partum or shortly thereafter; organ 
weights were recorded for brain, spleen and thymus.  
For males surviving to scheduled necropsy, sperm was assessed for motility and morphology plus one 
testis and epididymis was frozen for enumeration of homogenisation-resistant spermatids and cauda 
epididymal sperm reserves. For females, the ovaries and uterus were examined prior to fixation and 
the number of corpora lutea and implantation sites recorded.  
Each  litter  was examined for  number  of live  and dead  pups  as  soon  as  possible  after  birth. The 
individual weights of all live pups were recorded at day 1, 4, 7, 14 and 21. The sex of all pups was 
recorded, as was the number with any physical or behavioural abnormality. For the F1 weanlings 
selected for mating the day of vaginal opening or balanopreputial separation was recorded.  
Reproductive parameters recorded were percentage mating, fertility index, conception rate, gestation 
index, duration of gestation, percentage live offspring by sex, percentage of post-natal loss, percentage 
of breeding loss, percentage live at weaning by sex, viability index, weaning index.  
There were no differences between treated and control animals in any of the indices of reproductive 
performance or in the results of the sperm morphology and motility measurements. 
Males  of  the  F0  generation  given  30 mg/kg  bw/day  had  increased  relative  kidney  weights. 
Histopathology of the male kidneys showed changes typical of  2u -globulin nephropathy at all doses. 
No other histopathological changes were reported and no similar changes were observed in females.  Safety assessment of carvone 
 
EFSA Journal 2014;12(7):3806  47 
Males of the F1 generation given 30 and 90 mg/kg bw/day had increased mean relative liver and 
kidney  weights.  Histopathology  of  the  male  kidneys  showed  changes  typical  of  2u  -globulin 
nephropathy at all doses. No differences were seen in females and no other histopathological changes 
were reported.  
A review of findings in female rats by Verhaar (2005) considered the results of the 90-day study in the 
context  of  these  reproduction  study  data,  suggesting  that  none  of  the  effects  in  females  were  of 
concern. 
4.2.2.5.  Genotoxicity 
Carvone  showed  equivocal  results  for  mutagenicity  in  a  sister  chromatid  exchange  study  and  a 
chromosomal aberration study with Chinese hamster ovary cells. Results from an in vivo UDS assay in 
liver and an in vivo micronucleus test were negative while those of an in vitro test for chromosome 
aberrations were not clear-cut. Overall, in all reviews cited below, it was concluded that carvone 
should not be considered genotoxic (Florin et al., 1980; Mortelmans et al., 1986; NTP, 1990; Rockwell 
and Raw, 1979; Matsui et al., 1989, US-EPA, 2009; ECHA, 2013); the EFSA Scientific Committee 
sees no reason to review that conclusion. 
4.2.3.  Selection of the critical endpoint(s) 
Previous evaluations did not identify any specific critical toxicological endpoint, however all studies 
which tested doses in excess of 750 mg/kg bw per day have shown mortality in the treated animals. 
The deaths occurred within a short time after commencement of dosing. There is limited evidence of 
effects on liver and kidneys at the fatal doses and there is no histopathological indication as to the 
cause of death. Clinical observations prior to death indicate some impaired neural functions (ataxia, 
grip loss, righting loss) but the mechanism of that is uncertain. In the absence of links between effects 
at lower doses and the mortality observed at higher doses, the Scientific Committee considered that 
several effects recorded in subchronic studies may be used as markers for that toxicity. These include 
increases in relative liver and kidney weights, adverse effects on the sperm parameters and testes 
morphology, reduction of prothrombin time (PT) and increase of partial thromboplastin time (PTT).  
There is in vivo evidence to suggest that the molecular basis of the increase in liver and kidney weight 
is related to the capacity of carvone to induce antioxidant and detoxification enzymes in liver and 
kidney (i.e superoxide dismutase, glutathione S-transferases), which might be viewed as an adaptive 
rather  than  adverse  response.  There  is  however  no  established  link  between  that  effect  and  the 
mortality seen at higher doses. 
Effects on kidney weight are seen in both NTP and Schoenmakers studies and are considered related 
to treatment. Effects on the kidney of male rats (increased weight and histopathology) at 30 and 
180 mg/kg bw/day in the Schoenmakers study are related to  2u -globulin nephropathy and as such are 
not considered to be relevant to humans (Swenberg, 1993). The pathology report from the NTP study 
in rats identifies some renal changes but does not identify these lesions. This may represent a strain 
difference in effect between the two studies, however the F344 rat has been shown to be susceptible to 
2u -globulin nephropathy in studies of limonene toxicity, so the difference between the two studies 
remains unexplained. Due to the confounding nature of the  2u -globulin nephropathy on the difference 
in weight of kidneys, the effects on the kidney for male rats are excluded as a critical endpoint for 
analysis. The increased relative kidney weights in female rats in both NTP and Schoenmakers studies 
recorded at doses ranging from 30 mg/kg bw/day to 375 mg/kg bw/day, although not accompanied by 
any histopathological change, are regarded by the SC as reproducibly treatment-related. 
The effects on sperm and testis seen in the NTP study at doses of 375 mg/kg bw/day and above were 
not seen at lower doses in that study (  187 mg/kg bw/day) or in subsequent investigations at lower 
doses.  Specific  reproduction  studies  have  identified  no  treatment-related  effects  on  reproductive Safety assessment of carvone 
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performance at doses up to 30 mg/kg bw per day but confirmed the  2u -globulin nephropathy in male 
rats at all doses. The effects on sperm and testis in subchronic studies are thus not regarded as pivotal 
(or key) endpoints for the risk assessment since for other end-points effects were seen at lower doses. 
There is evidence of a decrease of PT in males at high doses, suggesting an inhibition of protein 
synthesis. An increase of PTT was observed in females at high doses, which suggests some effect of 
carvone on the blood coagulation pathway. These effects are considered likely to be secondary to any 
effects on liver and/or kidney and thus are not used in further analyses. 
In assessing the safety of carvone for the consumer from the available studies, the effects on relative 
liver weight (in both sexes) and relative kidney weight (in females) are considered by the SC as 
suitable  markers  for  toxicity  despite  being  relatively  minor  effects.  Since  toxicity  studies  with  l-
carvone are not available, the following BMD analysis only applies to d-carvone. 
While there is no direct link to any histopathological change or to the mortality seen at higher doses, 
effects on liver can be seen in males and females, both at the molecular and organ level in two species 
(rat and mice). Therefore the Scientific Committee decided to consider this endpoint as the most 
reliable marker of toxicity of d-carvone and to use the ratio of liver weight to body weight (relative 
liver weight) for benchmark dose modelling.  
The lack of renal effects in mice which also died at doses of 1 500 mg/kg bw/day and above suggest 
that renal effects may not be the underlying cause of the severe toxicity seen at high doses. However, 
on a conservative basis, the effects on relative kidney weight are also considered for benchmark dose 
modelling.  
4.2.4.  Dose-response assessment 
The Scientific Committee performed a BMD analysis on the relative liver weights for both male and 
female rats, and on the relative kidney weights for female rats (for details see Appendices A, B and C).  
A 95% lower confidence limit for the benchmark dose response of 10% (BMDL10) of 60 mg/kg 
bw/day was calculated for relative liver weight changes induced by d-carvone.  
For relative kidney weight changes, the Scientific Committee calculated a BMDL10 of 4.4 mg/kg 
bw/day; the Scientific Committee notes however that the confidence interval around the BMD10 (4.4 – 
65.8 mg/kg bw/day) is rather wide, indicating a considerable uncertainty of the estimate due to the fact 
that the variations in relative kidney weights are small, i.e, the effects are not much larger than the 
noise in the data. Although the use of the kidney effects leads to the lowest BMDL10 and would 
represent a conservative approach, in considering the poor quality of available data, the Scientific 
Committee  concluded  that  the  kidney  effects  seen  in  the  rat  are  an  unreliable  basis  for  the  risk 
assessment and that further data would be required to clarify the significance of those changes.  
4.2.5.  Establishment of an ADI 
Following the above considerations, the liver effects are considered to be the most relevant marker for 
the toxicity of d-carvone and are considered as the critical effect for hazard characterisation since: 
o  Liver effects occur in all species tested 
o  Liver effects are typical of other related molecules (e.g. limonene, pulegone, menthol) 
o  There are some secondary effects such as alterations of PT and PTT that may be related to liver 
toxicity Safety assessment of carvone 
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The Scientific Committee notes however the absence of information on the mode of action for d-
carvone and therefore, is unable to conclude whether this endpoint can be associated with the lethality 
observed at higher doses. 
The BMD modelling results in a BMDL10 for increased relative liver weight in the rat 90-day studies 
of  60  mg/kg  bw/day,  and  the  Scientific  Committee  selected  this  value  as the  reference point  for 
establishing  an  ADI.  Applying  the  default  uncertainty  factor  of  100  to  the  reference  point,  the 
Scientific Committee established an ADI of 0.6 mg/kg bw/day for d-carvone. When deriving an ADI 
from a sub-chronic toxicity study, an additional uncertainty factor of 2 is recommended to take into 
account extrapolation from sub-chronic to chronic effects, while additional uncertainty factor to take 
account of deficiencies in the data available for the assessment should be considered on a case-by-case 
basis (EFSA Scientific Committee, 2012). The Scientific Committee concluded that no additional 
uncertainty factor was necessary for this assessment, based on the following rationale: 
  Carvone is eliminated rapidly in humans (plasma half-life of 2.4 hours) via urine  
  The reference point used to calculate the ADI is derived from relative liver weight change in 
the rat with no histopathological evidence of toxicity. 
  The 2-year NTP toxicology study in mice (NTP, 1990) did not demonstrate clear d-carvone-
related effects at doses 12.5-fold above the BMDL10. 
Even though the acute toxicity data suggest that l-carvone is not more toxic than d-carvone, there are 
no repeat dose toxicity data available for this enantiomer. The Scientific Committee noted that JECFA 
in  its  2000  evaluation  of  l-carvone,  used  a  NOEL  of  125  mg/kg  bw/day  (Hagan  et  al.  1967), 
acknowledging that the enantiomer ratio was unspecified but assuming that l-carvone was the only 
enantiomer  commercially  available  at  the  time  of  that  study.  However  there  are  a  number  of 
uncertainties associated with this evaluation, particularly related to the identity of the material tested. 
The Scientific Committee did not use this reference point for l-carvone and concluded that an ADI 
cannot be established for l-carvone.  
4.3.  Risk characterisation 
People are also exposed to carvone dermally and through inhalation via consumer products, which will 
lead to an additional internal exposure. The Scientific Committee has assessed the exposure only via 
the oral route because the methodology to calculate the total exposure via different routes (i.e. dermal 
and inhalation exposure) would need at least information on absorption rates / kinetics in rodents and 
humans to estimate total internal exposure. Such information was not available. 
4.3.1.  d-Carvone 
The total aggregate exposure estimates in Table 9 (scenario 1) show that the highest exposure level to 
d-carvone from current uses (feed additive, pesticides, food flavourings, natural food occurrence and 
personal care products) is 0.59 mg/kg bw/day for high-level children consumers, which is marginally 
higher than that for high-level adult consumers (0.52 mg/kg bw/day). The highest exposure estimate is 
therefore at the level of the ADI established for d-carvone (0.6 mg/kg bw/day). When considering the 
anticipated exposure from intended pesticide uses on ware and starch potatoes (scenario 2), the highest 
exposure estimate would become 0.60 mg/kg bw/day, which is still at the level of the ADI for d-
carvone.  
It is important to note that the ADI was derived from a toxicological endpoint (increase of relative 
liver weight without histopathological effects) which is considered to be a marker for  toxicity but 
whose biological relevance, in relation to lethality at higher doses, is unknown.  Safety assessment of carvone 
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Although the ADI established for d-carvone is associated with a significant amount of uncertainty (see 
section 4.4), it is the most appropriate value that can be established from the available data. Further 
studies investigating the kinetics of d-carvone in the rat and studies to clarify the mode of action 
leading to mortality are required to refine the risk assessment, i.e. to allow for a better selection of the 
most appropriate endpoint and to decide on the suitability of the rat as a model for human risk 
assessment.  
4.3.2.  l-Carvone 
The total aggregate exposure estimates in Table 9 (scenario 4) show that the highest exposure level to 
l-carvone from all uses (natural food occurrence, flavourings, pesticides, personal care products) is 
1.87 mg/kg bw/day for high-level adult consumers. The exposure to l-carvone of toddlers and children 
is only slightly lower (1.27 and 1.23 mg/kg bw/day respectively). Such exposure is approximately 
three-fold higher than that of d-carvone. 
Because of the lack of toxicity data, the Scientific Committee could not establish an ADI for l-carvone 
and considers necessary to obtain a toxicological datapackage for l-carvone for the assessment of this 
enantiomer. 
4.4.  Uncertainty Analysis 
The  following  sources  of  uncertainties  are  associated  with  this  assessment  of  carvone.  They  are 
organised according to the various steps of the risk assessment.   
4.4.1.  Toxicokinetics 
  In vitro data and in silico assessments showed that carvone is metabolised at another site of 
the molecule in rats compared with humans. In addition, read-across comparison from in vivo 
metabolism  data  for  menthol  in  the  rat  indicated  that  it  is  likely  that  carvone  and  its 
metabolites undergo entero-hepatic recirculation in the rat but not in humans, leading to a 
longer  elimination  of  carvone  in  the  rat  compared  with  humans.  Basing  the  human  risk 
assessment on rat data may therefore be conservative. 
  There is uncertainty relating to the limited information on stereoselective metabolism in the 
rats and humans. 
4.4.2.  Hazard identification 
  The outcome of the toxicological studies for d-carvone in the rat with a lack of data on the 
mode of action bring uncertainties in the selection of the critical endpoint to be used for the 
risk assessment. The biological relevance of the relative liver weight increase (which is not 
linked to histopathological evidence of toxicity) as a marker of the mortality observed in rats 
at  higher  doses  is  arguable.  This  uncertainty  on  the  critical  endpoint  may  lead  to  an 
overestimation of the risk.  
  The  lack  of  toxicity  data  for  l-carvone  does  not  allow  for  assessing  the  safety  of  this 
enantiomer. 
4.4.3.  Hazard characterisation 
  There is uncertainty arising from the dose-response models used for the BMD analysis. The 
selection of the lowest BMDL from all models with an acceptable fit as the reference point for 
d-carvone is conservative. Safety assessment of carvone 
 
EFSA Journal 2014;12(7):3806  51 
  The use of the the liver data to identify a reference point for establishing an ADI for d-
carvone, and not the kidney data, may lead to an underestimation of the risk as the latter 
would lead to a lower reference point, although associated with a higher level of uncertainty 
(broader BMD confidence interval - see section 4.2.4.2). 
4.4.4.  Exposure assessment 
According to the guidance provided by the EFSA Scientific Committee (2006), the following sources 
of uncertainties have been considered.  
-  Input data: 
  Data  on  the  occurrence  of  carvone  rely  on  literature  or  information  provided  by 
stakeholders. Some of the papers report the occurrence of carvone without specifying the 
enantiomers. In many cases, the number of samples of natural sources analysed is rather 
limited. 
  Food consumption data: the data used for the exposure estimates were reported at the 
individual level in several different dietary surveys that applied different methodologies. 
Under-reporting and/or misreporting often represent a bias in dietary surveys.  
  Food nomenclature: the food nomenclatures used in the dietary surveys considered and 
then the FoodEx nomenclature used in the Comprehensive database are different from the 
Food Classification System developed for the definition of food flavourings uses in the 
Commission Regulation (EC) N° 1565/2000. Therefore, linking between different food 
nomenclatures may lead to uncertainties.  
  Reported use levels and concentration data: the estimates calculated are considered as 
being conservative because they are based on the assumption that every product within a 
given food category contains d- or l-carvone.  
-  Single source exposure: 
  Use as pesticide: the use of residue levels resulting from a 0-day waiting period after the 
last application when estimating the exposure to l-carvone from the use of spearmint oil is 
conservative, while considering the residue levels after a 2-3 weeks waiting period when 
estimating the anticipated exposure to d-carvone from its intended use on ware and starch 
potatoes may underestimate the real exposure of European consumers. 
  Use as pesticide: considering that all potato-based products are consumed unpeeled, while 
the processing studies of the DAR shown that >90% of the carvone residue resides on the 
potato peel is conservative. 
  Personal care products: the extrapolation of the exposure values calculated for toothpaste 
and mouthwash for adults to children is a source of uncertainty. It is unclear whether such 
assumption over or underestimates the children’s exposure to d- and l-carvone. 
-  Overall exposure to carvone 
  The  consideration  of  carvone  exposure resulting  only  from  oral  intake  underestimates 
European consumers’ exposure to carvone, as other routes of exposure, i.e. inhalation and 
dermal, are not taken into account. The magnitude of this underestimation is unknown. 
4.4.5.  Summary of uncertainties 
A summary of the uncertainty evaluation is presented in Table 12, highlighting the main sources of 
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led 
to an over- or underestimation of the exposure or the resulting risk. Safety assessment of carvone 
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Table 12:   Summary of qualitative evaluation of the impact of uncertainties on the risk assessment of 
the oral exposure to carvone. 
Sources of uncertainty  Direction
(a)  
    Hazard assessment   
Use of the rat model for human risk assessment  + 
Lack of in vivo toxicokinetic data in the rat and humans for both d- and l-
carvone 
+/- 
Lack of toxicity data for l-carvone  ? 
Selection of the relative liver weight increase as a marker of toxicity with no 
histopathological  changes  in  test  animals  and  as  critical  endpoint  for  the 
assessment 
+ 
Selection of the lowest BMDL10 value from all the models with an acceptable 
fit as reference point to derive the ADI  
+ 
Use of the reference point derived from the liver data for the assessment, 
while the kidney data would give a lower reference point, although the 
confidence interval around the BMD is much broader 
+/- 
   
    Exposure assessment   
Nature  of  the  occurrence  data  depending  on  the  legal  framework  and 
available  data  considered:  use  levels  versus  supervised  residue  trial  data 
versus actual concentration measurements 
+/- 
Consumption  data:  different  methodologies  /  representativeness  /  under 
reporting / misreporting / no portion size standard  +/- 
Extrapolation from food consumption survey of few days to estimate chronic 
exposure  + 
Linkage  between  reported  use  levels  and  food  items  in  the  consumption 
database: assumption that all products within a given food category contain 
d- or l-carvone at the level of concentration use/reported/monitored 
+ 
Natural  occurrence:  all  tea  and  infusions  consumed  are  prepared  from 
Mentha spicata (containing l-carvone)  . 
Use of the residue level resulting from a 0-day waiting period after the last 
application  for  the  estimation  of  exposure  to  d-carvone  when  used  as 
pesticide 
+ 
Use of the residue level resulting from a 2-3 weeks waiting period after the 
last application for d-carvone for anticipating the exposure to d-carvone from 
intended pesticide use on ware and starch potatoes 
- 
No processing factor or ingredient factor applied to potato-based products 
when estimating exposure to carvone from pesticide use  + 
All pork-based products containing d-carvone residues at the LOD level  . 
Adults’  daily  amounts  of  carvone  from  toothpaste  and  mouthwash 
extrapolated to the whole population  +/- 
Consideration of oral exposure only; absence of data allowing for calculating 
internal doses to combine oral exposure with dermal and inhalatory exposure 
- 
 
(a):  + = uncertainty with potential to cause over-estimation of exposure/risk;  
  - = uncertainty with potential to cause under-estimation of exposure/risk 
  . = uncertainty with negligible impact 
  ? = impact cannot be assessed 
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The Scientific Committee stresses the lack of toxicity data on l-carvone as a major uncertainty for this 
assessment. As such, the Scientific Committee is unable to decide whether d- and l-carvone should be 
assessed together and cannot establish a single ADI for carvone. 
The Scientific Committee acknowledges the uncertainties associated with the assessment of d-carvone 
(lack of data on the mode of action of d-carvone leading to the lethality observed in tested animals, 
only oral intake considered for the exposure assessment). However, since the relevance of the selected 
critical  endpoint  to  humans  and  its link  to  the  observed  mortality  is  unclear,  and  since  the  oral 
exposure assessment is an overestimate, overall, the Scientific Committee considers that the risk from 
oral exposure to d-carvone is likely to be an overestimate.  
CONCLUSIONS 
The conclusions below are addressing the three separate requests in the Terms of Reference. 
The Scientific Committee decided to consider d- and l-carvone separately for the hazard and exposure 
assessment. Furthermore, in view of an expected request for extending the application of d-carvone as 
a pesticide (sprout inhibitor) to ware and starch potatoes; the Scientific Committee decided to include 
this use in its assessment.  
Establishment of an ADI for carvone 
Based on two different data sets, different ADIs were established in the past for carvone by different 
risk assessment bodies: the JECFA and the EU pesticide peer review.  
The Scientific Committee considered both data sets for d-carvone and performed BMD modelling of 
relative liver weight changes (both data sets; male and female data included) and of relative kidney 
weight changes (both data sets, female data only). It was noted that the dose-response curves of the 
two studies (which were widely separated in time and place) were identical for the liver effects, but 
differed significantly for the kidney effects. The liver effects are considered to be the most likely 
relevant endpoint to be used as the basis for risk assessment of d-carvone because 1) liver effects 
occur  in  all  species  tested;  2)  liver  effects  are  typical  of  other  related  molecules  (e.g.  limonene, 
pulegone, menthol); and 3) there are some secondary effects related to liver toxicity such as alterations 
of PT and PTT. The Scientific Committee established an ADI of 0.6 mg/kg bw/day for d-carvone, 
based on the BMDL10 of 60 mg/kg bw/day for an increase in relative liver weight in the rat 90-day 
studies and an uncertainty factor of 100 (see chapters 4.2.2 to 4.2.5).  
The Scientific Committee could not establish an ADI for l-carvone because of a lack of toxicological 
data for this enantiomer. 
Overall oral exposure of European consumers and risk characterisation 
The Scientific Committee considered oral exposure of humans to carvone from: 
  its presence in natural sources through the diet where it is a normal constituent,  
  its current and intended use as a pesticide, 
  its use as flavouring substances,  
  its use as a feed additive,  
  its use as a (veterinary) medicinal product,  
  its use in personal care products (toothpaste, mouthwash).  
 
It is noted that the Scientific Committee could not address the non-oral exposure to carvone. It is 
unknown to what extent the non-oral exposure would contribute to the overall exposure. Safety assessment of carvone 
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Based on the available data the Scientific Committee concluded that the highest aggregate exposure 
estimate of d-carvone  from  current  uses (feed additive, pesticides, food flavourings,  natural food 
occurrence  and  personal  care  products)  is  0.59 mg/kg  bw/day  for  high-level  children  consumers, 
which is marginally higher than that for high-level adult consumers (0.52 mg/kg bw/day). The highest 
exposure estimate for d-carvone is therefore at the level of the ADI established for d-carvone. This 
high exposure estimate is not impacted by the anticipated exposure from additional pesticide use as 
anti-sprouting agent on ware and starch potatoes.  
The highest level of aggregated exposure to l-carvone is estimated to be 1.87 mg/kg bw/day for high-
level adult consumers. It is noted that this value is three fold that of d -carvone exposure. No risk 
characterisation could be done for l-carvone in the absence of adequate toxicity data. 
Contribution of each source of exposure to the overall exposure to carvone 
The Scientific Committee concluded that the main contributors (contributing over 10%) to the current 
overall oral exposure to d-carvone are in decreasing order: flavourings, personal care products, natural 
sources. Inclusion of exposure from the intended use of d-carvone as anti-sprouting agent on ware and 
starch potatoes does not result in an exceedance of the ADI.  
The main contributors to the overall oral exposure to l-carvone are in decreasing order: personal care 
products and flavourings. 
Overall conclusion 
The Scientific Committee established an ADI for d-carvone of 0.6 mg/kg bw/day by applying a default 
uncertainty factor of 100 to the BMDL10 of 60 mg/kg bw/day for an increase in relative liver weight in 
the rat 90-day studies. The Scientific Committee concluded that the aggregated exposure of European 
consumers to d-carvone could be up to the level of the ADI for d-carvone.  
The Scientific Committee was unable assess the safety of l-carvone or to to establish an ADI due to 
the lack of toxicity data; the Scientific Committee noted that the aggregated exposure to l-carvone is 
three-fold that of d-carvone. In the absence of data, the safety of l-carvone cannot be assumed. 
The Scientific Committee underlined the key uncertainties 1) on the toxicity of l-carvone, 2) on the 
biological relevance of the endpoint selected to establish the ADI for d-carvone and its use as a 
surrogate  for  the  observed  lethality  in  tested  animals,  3)  whether  d-  and  l-carvone  should  be 
considered together for possible combined effects and 4) in the aggregated exposure assessments to d- 
and to l-carvone, because the exposure via dermal contact and .inhalation is not included in the current 
assessment.  
RECOMMENDATIONS 
The Scientific Committee recommends generating the following data to reduce the level of uncertainty 
and to refine the current risk assessment: 
  Toxicokinetic  data  for  d-  and  l-carvone  in  rats.  Such  studies  would  provide  a  basis  for 
determining the metabolic profile and elimination patterns of both enantiomers (clearance, 
half life). In addition, such studies would test the hypothesis that enterohepatic recirculation of 
carvone metabolites (glucuronides) occurs in the rat, quantify any interspecies differences in 
toxicokinetics between humans and rats, and as such, would allow to confirm the statement 
made in this opinion that the rat may be more sensitive than humans to carvone. 
  Toxicity data for l-carvone. Safety assessment of carvone 
 
EFSA Journal 2014;12(7):3806  55 
  Studies investigating the mode of action of both d- and l-carvone and addressing the relative 
toxicity  of  the  enantiomers.  This  information  is  necessary  to  decide  whether  the  two 
enantiomers should be considered together to establish a group ADI (see glossary). 
  Validation of the concentration data from all sources used for the oral aggregated exposure 
assessment for d- and l-carvone; priority should be given to the main contributory sources 
(>10%), i.e., by decreasing order: 
o  for  d-carvone:  meat  and  meat  products,  milk  and  dairy  products,  fish  and  other 
seafood, alcoholic and non-alcoholic beverages for flavouring substances and herbs, 
spices and condiments for natural food occurrence and toothpaste for personal care 
products 
o  for l-carvone: mouthwash and toothpaste for personal care products and milk and 
dairy products, snacks and desserts and alcoholic and non-alcoholic beverages for 
flavouring substances. 
  Develop models to perform aggregate exposure assessment from different routes (oral-dermal-
inhalation).  In  order  to  do  this,  data  providing  information  on  the  relationship  between 
external and internal exposure for different routes are needed. 
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APPENDICES  
Appendix A.   Liver data considered for the assessment 
Table A1:  NTP 13-weeks oral toxicity test with d-carvone in Fischer 344 rats (1982) 
 
Dose (mg/kg)  Liver/Bodyweight ratio (%) 
Mean (SD) 
Liver/Bodyweight ratio (%) 
Median (Min, Max) 
Dose group / control Means 
Difference (95% CI) 
p-value
(a) 
Control - Males   3.50 (0.200)   3.42 ( 3.32,  3.89)     
93 mg/kg - Males   3.99 (0.200)   3.98 ( 3.73,  4.31)   0.49 (0.251, 0.723)  <0.001 
187 mg/kg - Males   4.13 (0.200)   4.10 ( 3.80,  4.54)   0.63 (0.393, 0.865)  <0.001 
375 mg/kg - Males   4.86 (0.180)   4.83 ( 4.65,  5.19)   1.36 (1.119, 1.590)  <0.001 
Control - Females   2.96 (0.170)   2.99 ( 2.68,  3.24)     
93 mg/kg - Females   3.39 (0.240)   3.30 ( 3.17,  3.97)   0.43 (0.126, 0.726)  0.003 
187 mg/kg - Females   3.47 (0.140)   3.43 ( 3.29,  3.75)   0.51 (0.210, 0.809)  <0.001 
375 mg/kg - Females   4.19 (0.370)   4.07 ( 3.76,  4.89)   1.23 (0.927, 1.527)  <0.001 
(a): Tukey’s multiple comparisons of means (compared to the control group) Safety assessment of carvone 
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Table A2: DAR 90-day oral toxicity test with d-carvone in Wistar rats (Schoenmakers, 1996) 
 
Dose (mg/kg)  Liver/Bodyweight ratio (%) 
Mean (SD) 
Liver/Bodyweight ratio (%) 
Median (Min, Max)) 
Dose group / control Means 
Difference (95% CI) 
p-value
(a) 
Control - Males   2.95 (0.300)   2.95 ( 2.39,  3.60)     
5 mg/kg - Males   2.83 (0.110)   2.81 ( 2.63,  3.00)  -0.12 (-0.407, 0.161)  0.652 
30 mg/kg - Males   2.94 (0.270)   2.93 ( 2.58,  3.38)  -0.01 (-0.299, 0.270)  0.999 
180 mg/kg - Males   3.24 (0.220)   3.19 ( 2.97,  3.67)   0.29 (0.005, 0.573)  0.045 
Control - Females   2.75 (0.220)   2.70 ( 2.33,  3.10)     
5 mg/kg - Females   2.78 (0.260)   2.72 ( 2.55,  3.40)   0.03 (-0.251, 0.324)  0.986 
30 mg/kg - Females   3.09 (0.280)   3.05 ( 2.59,  3.49)   0.34 (0.054, 0.629)  0.015 
180 mg/kg - Females   3.23 (0.190)   3.22 ( 2.98,  3.54)   0.48 (0.197, 0.773)  <0.001 
(a): Tukey’s multiple comparisons of means (compared to the control group) 
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Appendix B.   Kidney data considered for the assessment 
Table B1: NTP 13-weeks oral toxicity test with d-carvone in Fischer 344 rats (1982) 
 
Dose (mg/kg)  Kidney/Bodyweight ratio (%) 
Mean (SD) 
Kidney/Bodyweight ratio (%) 
Median (Min, Max) 
Dose group / control Means 
Difference (95% CI) 
p-value
(a) 
Control - Males   0.31 (0.020)   0.30 ( 0.28,  0.34)     
93 mg/kg - Males   0.32 (0.020)   0.32 ( 0.28,  0.34)   0.01 (-0.008, 0.033)  0.384 
187 mg/kg - Males   0.34 (0.010)   0.33 ( 0.32,  0.36)   0.03 (0.009, 0.051)  0.002 
375 mg/kg - Males   0.38 (0.010)   0.38 ( 0.36,  0.41)   0.07 (0.054, 0.096)  <0.001 
Control - Females   0.32 (0.020)   0.32 ( 0.29,  0.35)     
93 mg/kg - Females   0.34 (0.020)   0.33 ( 0.31,  0.38)   0.02 (-0.011, 0.044)  0.38 
187 mg/kg - Females   0.34 (0.020)   0.34 ( 0.32,  0.37)   0.02 (-0.006, 0.048)  0.179 
375 mg/kg - Females   0.36 (0.030)   0.37 ( 0.33,  0.43)   0.04 (0.017, 0.071)  <0.001 
(a): Tukey’s multiple comparisons of means (compared to the control group) 
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Table B2: DAR 90-day oral toxicity test with d-carvone in Wistar rats (Schoenmakers, 1996) 
 
Dose (mg/kg)  Kidney/Bodyweight ratio (%) 
Mean (SD) 
Kidney/Bodyweight ratio (%) 
Median (Min, Max) 
Dose group / control Means 
Difference (95% CI) 
p-value
(a) 
Control - Males   0.58 (0.050)   0.57 ( 0.52,  0.67)     
5 mg/kg - Males   0.60 (0.050)   0.59 ( 0.52,  0.67)   0.02 (-0.067, 0.108)  0.921 
30 mg/kg - Males   0.66 (0.050)   0.66 ( 0.59,  0.76)   0.08 (-0.000, 0.175)  0.051 
180 mg/kg - Males   0.87 (0.110)   0.88 ( 0.64,  1.06)   0.29 (0.205, 0.381)  <0.001 
Control - Females   0.56 (0.040)   0.56 ( 0.51,  0.60)     
5 mg/kg - Females   0.57 (0.050)   0.55 ( 0.52,  0.65)   0.01 (-0.060, 0.074)  0.993 
30 mg/kg - Females   0.64 (0.060)   0.66 ( 0.54,  0.72)   0.08 (0.016, 0.150)  0.01 
180 mg/kg - Females   0.68 (0.070)   0.67 ( 0.59,  0.80)   0.12 (0.050, 0.184)  <0.001 
(a): Tukey’s multiple comparisons of means (compared to the control group) Safety assessment of carvone 
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Appendix C.   Dose-response modelling 
The details of the benchmark dose (BMD) analysis for the hazard characterisation of d-carvone are 
presented in this Appendix.  
The  BMD  approach  was applied to the  dose-response  data  of  the  NTP  (1982)  and  Schoenmaker 
(1996) 90-day studies in rats (see section 4.2.2.2). Relative liver weights and relative kidney weight 
changes were identified as critical endpoints. In the case of the relative liver weights, four subgroups 
were distinguished: males and females in each of the two studies. For the relative kidney weights, only 
the females in each of the two studies were considered for dose-response modelling, since the kidney 
effect observed in male rats was concluded to be not relevant to humans (see section 4.2.3). The 
individual data were used for modelling.  
The BMD analysis was performed in line with EFSA guidance on benchmark dose modelling (EFSA 
Scientific Committee, 2009), using PROAST version 40.7 (www.proast.nl). The default assumptions 
in the software were left unchanged. Although the EFSA Scientific Committee recommends using a 
default  benchmark  response  (BMR)  value  of  5  %  for  continuous  data  from  animal  studies,  the 
Scientific  Committee  noted  that,  in  both  the  NTP  (1982)  and  the  Schoenmakers  (1996)  studies, 
statistically significant increases in relative liver (in both male and female rats) and relative kidney 
weights  (in  female  rats)  were  not  accompanied  by  any  histopathological  changes,  and  therefore 
decided to use a BMR of 10% for the BMD analysis. The exponential and the Hill model were applied 
as nested families of models, where the number of model parameters is based on the analysis of the 
specific data. Within a given family, the preferred model is the one with the fewer parameters if it does 
not show a significantly poorer fit compared to models with one more parameter.  
The  PROAST  software  offers  the  possibility  to  directly  (and  statistically)  compare  dose-response 
relationships between different subgroups. The statistical analysis addresses the question of whether 
the different subgroups can be described by the same dose-response curve, and if not, in what sense 
the curves differ from each other. The software establishes which parameters should be subgroup 
dependent,  based  on  a  significant  improvement  of  the  fit  (likelihood  ratio  test).  Next,  the  BMD 
confidence intervals are computed for each of the subgroups. It should be noted that in situations 
where the curves differ among subgroups only in their background responses, the subgroups share the 
same BMD. This holds true for the relative liver weight endpoint (see Figure 3): the relative liver 
weights were found to differ significantly in background levels only, leading, for a given mathematical 
model, to a single BMD for the relative liver weight endpoint, independently of the sex or the study 
considered. A combined analysis of related datasets enhances the precision of the BMD calculation, as 
the number of animals per dose-group is increased to estimate the BMD (or other parameters in the 
dose-response  model).  As  a  result,  BMD  confidence  intervals  tend  to  be  smaller  in  a  combined 
analysis.  
In the case of the relative kidney weights, the two studies are found to significantly (P = 0.03) differ in 
parameter b (sensitivity of the animals in that study). The two subgroups will therefore differ in BMDs 
and separate BMD confidence intervals have to be calculated. 
Relative liver weights 
The procedure described in the EFSA guidance on benchmark dose (choose minimal nested member 
of family of models) results in model 2 for the exponential family (y = a exp(bx); two-parameter 
model), while the Hill model results in model 3 (y = a [1 - xd/(bd+xd)]; three-parameter model) (see 
Table C1) Safety assessment of carvone 
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With the exponential model, the BMD10 is 113 mg/kg bw/day, with a confidence interval of 104.2-
122.8 mg/kg bw/day (BMDL10-BMDU10). 
With the Hill model, the BMD10 is 82.3 mg/kg bw/day, with a BMDL10-BMDU10 interval of 60-108.2 
mg/kg bw/day. 
The Scientific Committee selected the lowest BMDL10 (60 mg/kg bw/day) as the reference point for 
relative liver weight. The overall BMD confidence interval is 60 – 122.8 mg/kg bw/day. 
 
Table C1:  Summary of BMD analysis of liver weights
(a). The BMD confidence intervals are 
calculated for the selected model only.  
Model
(b)  log-
likelihood 
# parameters  Fit
(c)  BMD  BMDL  BMDU 
Full  209.70  17         
Full-v  217.48  20  > full       
Null-v  69.61  5         
Exponential family 
E2-av  203.82  9    113  104  123 
E2-abv  204.64  12  not > E2-av       
E3-av  205.60  10  not > E2-av       
E4-av  204.28  10  not > E2-av       
Hill family 
H2-av  202.60  9         
H2-abv  202.93  12  not > H2-av       
H3-av  206.39  10  > H2-av    82  60  108 
H4-av  204.27  10  not > H2-av       
   
Overall BMD CI :                                   (60, 123) 
 
(a):  The liver weights of the DAR_Schoenmakers study and the NTP study are analyzed as a combined dataset; the table 
relates to that combined analysis.
 
(b):  The letters after the hyphen in the model names indicate which parameters (a = background response, b = sensitivity to 
the chemical, v = within group variance) are assumed to depend on the subgroup.  
 
(c):  > means “significantly better than”. The principle of model selection is that it should fit significantly better than models 
with fewer parameters, but not significantly worse than models with more parameters.  Safety assessment of carvone 
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Figure C1: BMD modelling of relative liver weight changes induced by d-carvone  
Male  and  female  data  were  used.  Larger  marks:  geometric  means,  smaller  marks:  individual 
observations.  Diamonds:  DAR_Schoenmakers_1996/males,  crosses:  DAR_Schoenmakers_1996/ 
females, triangles: NTP/males, circles: NTP/females. The exponential model (left panel) and the Hill 
model (right panel) were fitted with subgroup dependent background response (parameter a) only. 
CED (critical effect dose) is the BMD at a 10% (BMR = Critical Effect Size (CES) = 0.1) increase, 
indicated by the four horizontal dashed lines. The vertical dashed line indicates the BMD estimate. 
CEDL and CEDU are the BMDL and BMDU, respectively. The parameter var (within group variance 
on ln-scale) was found to differ significantly among the four subgroups with larger values in the 
Schoenmakers (1996) study. This indicates that the variation in observations at a given dose group was 
smaller in the NTP study, possibly related to a more homogenous strain of animals, or related to more 
homogenous experimental circumstances, or smaller dosing errors, smaller measurement errors, etc.  
Relative kidney weights 
The procedure described in the EFSA guidance on benchmark dose (choose minimal nested member 
of family of models) results in model 5 (y = a [c – (c-1)exp( - bxd)]; four-parameter model) being 
selected for the exponential family, while model 4 (y = a [1 + (c-1)x/(b+x)]; three-parameter model) is 
selected for the Hill family. Safety assessment of carvone 
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Table C2:  Summary of BMD analysis of kidney weights
(a). The BMD confidence intervals are 
calculated for the selected models only. 
Model
(b)  log-
likelihood 
# parameters  Fit
(c)  BMD  BMDL  BMDU 
Full  79.63  9         
Full-v  80.33  10         
Null  -54.62  2         
Exponential 
family 
           
E2-ab  75.26  5  < E5-ab       
E5-a  75.93  6         
E5-ab  78.42  7  > E5-a  18  5.1  64 
Hill family             
H2-a  64.33  4         
H3-a  64.33  5  not > H2-a       
H4-a  75.74  5  > H2-a       
H4-ab  78.22  6  > H3-a  16  4.4  66 
   
Overall BMD CI for DAR study:         (4.4,  66) 
 
(a): The kidney weights of the DAR_Schoenmakers study and the NTP study are analyzed as a combined dataset; the table 
relates to that combined analysis. 
(b):  The letters after the hyphen in the model names indicate which parameters (a = background response, b = sensitivity to 
the chemical, v = within group variance) are assumed to depend on the subgroup.   
(c):  > means “significantly better than”, and  < means “significantly worse than”. The principle of model selection is that it 
should fit significantly better than models with fewer parameters, but not significantly worse than models with more 
parameters.  
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Figure C2:   BMD modelling of relative kidney weights changes induced by d-carvone Safety assessment of carvone 
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Female data only were used. Larger marks: geometric means, smaller marks: individual observations. 
Circles:  DAR_Schoenmakers_1996/females,  triangles:  NTP/females.  The  exponential  model  (left 
panel) and the Hill model (right panel) were fitted. CED (critical effect dose) is the BMD at a 10% 
(BMR = Critical Effect Size (CES) = 0.1) increase, indicated by the four horizontal dashed lines. The 
vertical dashed lines indicate the BMD estimates. CEDL and CEDU are the BMDL and BMDU, 
respectively. In this case, the parameter var (within group variance on ln-scale) was not found to differ 
significantly among the two subgroups, i.e., both studies showed similar scatter within dose groups.   
With the exponential model, the BMD10 resulting from the Schoenmakers (1996) study is 18.1 mg/kg 
bw/day  with  a  BMDL10-BMDU10  interval  of  5.1  –  64.3  mg/kg  bw/day  (Table  C2).  The  BMD10 
resulting from the NTP study is 253 mg/kg bw/day with a BMDL10-BMDU10 interval of 79.5 – 768.3 
mg/kg bw/day (Figure 4). 
With the Hill model, the BMD10 resulting from the Schoenmakers (1996) study is 15.9 mg/kg bw/day 
with a BMDL10-BMDU10 interval of 4.4 – 65.9 mg/kg bw/day (Table C2). The BMD10 resulting from 
the NTP study is 243 mg/kg bw/day with a BMDL10-BMDU10 interval of 70.7 – 852.8 mg/kg bw/day 
(Figure 4).  
The Hill model applied to the relative kidney weight data from Schoenmakers (1996) provides the 
lowest BMDL10 (4.4 mg/kg bw/day). However, the confidence interval around the BMD10 (4.4 – 65.9 
mg/kg bw/day) is rather wide, indicating a considerable uncertainty of the estimate due to the fact that 
the variations in relative kidney weights are small, i.e, the effects are not much larger than the noise in 
the data.  Safety assessment of carvone 
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Appendix D.   Carvone occurrence data (in mg/kg) in some of the food commodities (feed, pesticides current and intended uses and natural 
occurrence) used in the various scenarios (Tables 7 to 11) 
FOODEX_L4  Enantiomer  Feed* 
Pesticides 
intended use 
(d-carvone) 
Spearmint oil used as 
pesticide 
(/l-carvone) 
Natural food occurrence 1 
(d-carvone) 
Natural food occurrence 2 
(l-carvone) 
Natural food occurrence 3 
(d-carvone + unspecified in 
form of d-carvone) 
Natural food occurrence 4 
(l-carvone + unspecified in 
form of l-carvone) 
Natural food occurrence 5 
(l-carvone + unspecified in 
form of l-carvone + all 
infusion as mentha spicata 
in form of l-carvone) 
Celery  (Apium  graveolens 
var. dulce)  U            0,05  0,05  0,05 
Tea and herbs for infusions 
(Solid)  l                3233
 (a) 
Peppermint  (Mentha  × 
piperita)  l          3233
 (b)    3233
 (b)  3233
 (b) 
Oranges (Citrus sinensis)  U            0,055  0,055  0,055 
Mandarins  (Citrus 
reticulata)  U            0,015  0,015  0,015 
Pomelo (Citrus grandis)  U            0,029  0,029  0,029 
Guava (Psidium guajava)  U            0,025  0,025  0,025 
Jam,  Oranges  (Citrus 
sinensis)  U            0,0275
 (c)  0,0275
 (c)  0,0275 
(c) 
Marmalade,  Oranges 
(Citrus sinensis)  U            0,0275
 (c)  0,0275
 (c)  0,0275
 (c) 
Canned  fruit,  Mandarin 
(Citrus reticulata)  U            0,015  0,015  0,015 
Fruit  compote,  Mandarin 
(Citrus reticulata)  U            0,015  0,015  0,015 
Juice, Orange  U            0,055  0,055  0,055 
Juice, Grapefruit  U            0,029  0,029  0,029 
Juice concentrate, Oranges  U            0,055  0,055  0,055 
Nectar, Orange  U            0,055  0,055  0,055 
Juice, Orange-Grapefruit  U            0,042
 (d)  0,042
 (d)  0,042 
(d) 
Juice, Celery  U            0,05  0,05  0,05 
Fruit soft drink, Grapefruit  U            0,029  0,029  0,029 
Fruit soft drink, Orange  U            0,055  0,055  0,055 
Tea (Infusion)  l                32,33
 (a) 
Herbal tea, infusion  l                32,33
 (a) 
Dill,  herb  (Anethum 
graveolens)  d        3250 
(e)         
Celery  leaves  (Apium 
graveolens  var. 
seccalinum)  U            0,05  0,05  0,05 
Rosemary,  herb 
(Rosmarinus officinalis)  U            27  27  27 Safety assessment of carvone 
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FOODEX_L4  Enantiomer  Feed* 
Pesticides 
intended use 
(d-carvone) 
Spearmint oil used as 
pesticide 
(/l-carvone) 
Natural food occurrence 1 
(d-carvone) 
Natural food occurrence 2 
(l-carvone) 
Natural food occurrence 3 
(d-carvone + unspecified in 
form of d-carvone) 
Natural food occurrence 4 
(l-carvone + unspecified in 
form of l-carvone) 
Natural food occurrence 5 
(l-carvone + unspecified in 
form of l-carvone + all 
infusion as mentha spicata 
in form of l-carvone) 
Anise  seed  (Pimpinella 
anisum)  U            158  158  158 
Caraway (Carum carvi)  d        29694    29694     
Cinnamon  (Cinnamonum 
verum syn. C. zeylanicum)  d        3,4 
(f)    3,4
 (f)     
Dill  seed  (Anethum 
graveolens)  d        21017    21017     
New potatoes  d/l    3,9  1,2           
Main-crop potatoes  d/l    3,9  1,2           
Sweet  potatoes  (Ipomoea 
batatas)  d/l    3,9  1,2           
Potatoes  and  potatoes 
products  d/l    3,9  1,2           
French fries  d/l    3,9  1,2           
Potato flakes  d/l    3,9  1,2           
Mashed potato powder  d/l    3,9  1,2           
Potato boiled  d/l    3,9  1,2           
Potato fried  d/l    3,9  1,2           
Potato baked  d/l    3,9  1,2           
Potato croquettes  d/l    3,9  1,2           
Potato starch  d/l    3,9  1,2           
Potato flour  d/l    3,9  1,2           
Potato based dishes  d/l    3,9  1,2           
Potatoes  and  vegetables 
meal  d/l    3,9  1,2           
Potatoes and cheese meal  d/l    3,9  1,2           
Potato bread  d/l    3,9  1,2           
Potato-rye bread  d/l    3,9  1,2           
Fish and potatoes meal  d/l    3,9  1,2           
Potato soup  d/l    3,9  1,2           
Prepared potato salad  d/l    3,9  1,2           
Juice, Potato  d/l    3,9  1,2           
Potato crisps  d/l    3,9  1,2           
Potatoes and meat meal  d/l    3,9  1,2           Safety assessment of carvone 
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FOODEX_L4  Enantiomer  Feed* 
Pesticides 
intended use 
(d-carvone) 
Spearmint oil used as 
pesticide 
(/l-carvone) 
Natural food occurrence 1 
(d-carvone) 
Natural food occurrence 2 
(l-carvone) 
Natural food occurrence 3 
(d-carvone + unspecified in 
form of d-carvone) 
Natural food occurrence 4 
(l-carvone + unspecified in 
form of l-carvone) 
Natural food occurrence 5 
(l-carvone + unspecified in 
form of l-carvone + all 
infusion as mentha spicata 
in form of l-carvone) 
Potatoes,  meat,  and 
vegetables meal  d/l    3,9  1,2           
Pork  /  piglet  meat  (Sus 
scrofa)  d  0,04               
Mixed beef and pork meat  d  0,04               
Mixed  pork  and 
mutton/lamb meat  d  0,04               
Pork liver  d  0,04               
Pork kidney  d  0,04               
Tongue (beef, veal, mutton, 
lamb, pork)  d  0,04               
Heart  (beef,  veal,  pork, 
mutton, lamb)  d  0,04               
Brain (veal, lamb, pork)  d  0,04               
Spleen (beef, pork)  d  0,04               
Tail (beef, pork, lamb)  d  0,04               
Totters and feet (calf, pork)  d  0,04               
Ham, pork  d  0,04               
Pork, dried  d  0,04               
Corned pork  d  0,04               
Pastrami, pork  d  0,04               
Pork meat loaf  d  0,04               
Pate, pork liver  d  0,04               
Pork lard (Schmaltz)  d  0,04               
 
U =  unspecified 
(a):
 assuming that all infusion are mentha spicata basis 
(b):
 assuming that consumer does not differentiate spicata from piperita therefore all spicata 
(c):
  assuming 50% fruit content 
(d):
 assuming average of content from orange and grapefruit 
(e): assuming 25% of d carvone in essential oils of around 1.3% in dry herb 
(f):   assuming only bark content taken as reference 
*   assuming upper bound scenario (LOD of 0.04 mg/kg) 
 Safety assessment of carvone 
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GLOSSARY 
Aggregate exposure  The combined exposures to a single chemical across multiple routes (oral, 
dermal,  inhalation)  and  across  multiple  pathways  (food,  drinking-water, 
residential) 
Group Acceptable Daily 
Intake (ADI) 
An ADI established for a group of compounds that display similar toxic 
effects or share a common toxic metabolite, thus limiting their cumulative 
intake 
Lipinski's Rule of Five  Rule  of  thumb  to  evaluate  drug  likeness,  or  determine  if  a  chemical 
compound with a certain pharmacological or biological   activity  has 
properties that would make it a likely orally active drug in humans. The 
Lipinski rule of 5 states that a compound will have drug- like properties if it 
has: 
  Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms 
with one or more hydrogen atoms); 
  Not more than 10 hydrogen bond acceptors (nitrogen or oxygen 
atoms); 
  A molecular weight under 500 g/mol; 
  A partition coefficient log P less than 5 
Pesticide Residue 
definition 
The  evaluation  dossier  of  a  pesticide  active  substance  results  in  the 
establishment of two residue definitions, one for monitoring and one for 
dietary risk assessment. The residue definition for monitoring is used for 
the enforcement of the MRLs (Maximum Residue Levels) and must reflect 
analytical  practicalities.  In  many  cases,  only  the  parent  compound  is 
included in this definition, as a marker compound. The residue definition 
for dietary risk assessment is used to assess consumer safety, and it should 
therefore include all metabolites and degradates of toxicological relevance 
Starch potatoes  potatoes grown for the production of potato starch 
Ware potatoes  potatoes grown for human consumption (fresh or processed) 
 